

From: Boulmay, Christopher
Sent: Tuesday, November 30, 2010 4:00 PM
To: 'McAuliffe, John@CDCR'
Cc: Kernan, Scott@CDCR; Halpenny, Susan M; Dixon, Ruth P
Subject: RE: FDA entry item # 112-99-38358-2
John,

This entry is currently under review by our DIOP branch. (b) (5)
[REDACTED]. If you need additional information you can call Supervisor Susan Halpenny at 901-333-3521 or Supervisor Ruth Dixon at 901-333-3522. I am not authorized to make an admissibility decision on the entry.

Thank you,

Christopher Boulmay

Consumer Safety Officer
US Food & Drug Administration
NOL-DO: Memphis R.P.
Phone: (901) 333-3528
Fax: (901) 333-3577

From: McAuliffe, John@CDCR [mailto:John.McAuliffe@cdcr.ca.gov]
Sent: Tuesday, November 30, 2010 3:37 PM
To: Boulmay, Christopher
Cc: Kernan, Scott@CDCR
Subject: FDA entry item # 112-99-38358-2

Mr. Boulmay

I am inquiring into the shipment (# 112-99-38358-2) that is currently awaiting FDA approval. The shipment is to be sent to (b) (4)
[REDACTED] (b) (6) is the (b) (4) contact person) I also called your phone number 901-333-3528 and left a message. If you could please return my call I would like to know the timeline for release. Thank you in advance.

John McAuliffe
California Department of Corrections and Rehabilitation

Trepagnier, Timothy

From: Budweg, Greta L
Sent: Monday, September 27, 2010 12:02 PM
To: Halpenny, Susan M
Cc: Dixon, Ruth P; Thomas, David; Chan, Hoi-May (CBER); Samaan, Marian; Chung, Phap; Cowels, Allyson
Subject: RE: Lethal Injection Pharmacology

Susan,

We are running sweeps in CBP's ATS database to find this shipment prior to arrival. We've identified 2 similar shipments with our sweep with UPS-9066861-5 and 112-8992979-0. We'll keep you posted on anything we find.

Greta

Greta L. Budweg
Watch Commander
FDA/ORA/ORO/Prior Notice Center
866-521-2297 main phone
703-261-8439 phone
703-261-8625 fax
greta.budweg@fda.hhs.gov

-----Original Message-----

From: Halpenny, Susan M
Sent: Monday, September 27, 2010 12:44 PM
To: Thomas, David
Cc: Dixon, Ruth P; Budweg, Greta L
Subject: FW: Lethal Injection Pharmacology
Importance: High

Good day,

It would be helpful if you could provide Memphis the airway bill for this shipment. We can follow-up with the broker to see if/and when the shipment is being received. Also we would be able to track the shipment through (b) (4). I appreciate any information you can provide. Thanks.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521

Fax (901) 333-3576

-----Original Message-----

From: Budweg, Greta L
Sent: Monday, September 27, 2010 11:31 AM
To: Schafer, Patricia
Cc: ORA SE NOL Import Supervisors; Taube, Anthony C
Subject: FW: Lethal Injection Pharmacology
Importance: High

Hi Pat,

I suggested to Dave Thomas that this information would be helpful to the Memphis entry reviewers. Dave indicated that no entry has been made at this time. I'll continue to pass on any information related to this shipment.

Greta

Greta L. Budweg
Watch Commander
FDA/ORA/ORO/Prior Notice Center
866-521-2297 main phone
703-261-8439 phone
703-261-8625 fax
greta.budweg@fda.hhs.gov

-----Original Message-----

From: Thomas, David
Sent: Monday, September 27, 2010 11:50 AM
To: Budweg, Greta L
Subject: FW: Lethal Injection Pharmacology
Importance: High

Dave Thomas
FDA Imports
Phoenix, AZ

-----Original Message-----

From: Thomas, David

Sent: Monday, September 27, 2010 8:23 AM

To: Taube, Anthony C

Cc: Strickland, Evanguel; Solis, Daniel; 'DEAN, MICHAEL K';
'CHARLES FLANAGAN'

Subject: Lethal Injection Pharmacology

Importance: High

Prior Notice Center Director, Anthony Taube:

RE: Lethal Injection pharmacology:

Sir:

I have an entry of 3 components of a lethal injection, 1) Thiopental, 2) Pancuronium, 3) Potassium Chloride departing London this afternoon, destination Memphis with Port of Entry 2605, Phoenix. As of this communication, no entry has been made.

These pharmaceuticals are needed to carry out an execution here in Arizona, and are not for public consumption. Attached is Please find attached explanatory documentation and DEA registration for the Arizona Corrections facility.

Lastly, should I be advising anyone else?

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office

Charles:

We are in receipt of your communication and PDF attachments. I have CC'd my Supervisor, Mr. Strickland, and our Imports Director Mr. Solis for their review.

David Thomas, DCM
FDA Investigations
Phoenix, Office

-----Original Message-----

From: CHARLES FLANAGAN [mailto:CFLANAG@azcorrections.gov]

Sent: Friday, September 24, 2010 5:04 PM

To: Thomas, David

Subject: Pharmaceuticals from Dream Pharma, LTD. of London, England

Good Afternoon Mr. Thomas:

Thank you so much for your assistance with this matter. I have attached to this email a copy of the correspondence what will be shipped with the pharmaceuticals. It also includes the Department of Corrections' "Substance Control Registration Certificate". The second attachment is a list of the items that will be shipped to our facility; to include quantities purchased and the last attachment is the revised DEA Registration which includes certification for Schedule 2 drugs.

Once again, thank you again for your assistance. Should you require additional information, please do not hesitate to contact me. Here is my information:

Charles Flanagan
Deputy Director
Arizona Department of Corrections
1601 W. Jefferson - MC 445
Phoenix, Arizona 85007
(602) 542-3611 Office
(602) 377-5334 Cell
(602) 364-0601 Fax
cflanag@azcorrections.gov

OFFICE OF THE SECRETARY

P.O. Box 942883
Sacramento, CA 94283-0001



December 9, 2010

Ms. Ruth Dixon
Department of Health and Human Services
Food and Drug Administration

Dear Ms. Dixon:

Since 1993, California law has authorized capital punishment by lethal injection pursuant to Penal Code Section 3604. The law states the punishment of death shall be inflicted by the administration of an intravenous injection of substances in a lethal quantity sufficient to cause death. On May 1, 2009, the California Department of Corrections and Rehabilitation (CDCR) promulgated regulations setting forth the requirements for administering capital punishment by lethal injection pursuant to Administrative Procedure Act. Those regulations became effective on August 29, 2010. The regulations provide for the use of three chemicals; sodium thiopental, pancuronium bromide, and potassium chloride.

There is a national shortage of sodium thiopental. California, like many other states, has been actively seeking supplies of the sodium thiopental for future executions. California's supply of sodium thiopental expired on October 1, 2010. On November 22, 2010, CDCR notified the United States District Court for the Northern District of California that it had ordered (b) (4) grams of sodium thiopental that expires in 2014 from a manufacturer based in England (FDA # 112-99-38358-2). CDCR expected to receive the sodium thiopental during the week of November 29, 2010. Although CDCR followed all proper procedures and the Drug Enforcement Agency and United States Customs has approved the shipment, this shipment is currently be held by your office.

Per your conversation with John McAuliffe, we are asking for the immediate release and shipment of the (b) (4) grams of sodium thiopental. If you have any questions, concerns or any changes arise, please contact me at (916) 323-6001 or Mr. McAuliffe at (707) 480-6766.

Sincerely,

A handwritten signature in black ink, appearing to read "Ben T Rice", is written over a horizontal line.

BENJAMIN T. RICE
General Counsel

cc: John McAuliffe

From: John Solomon [Solomon.John@doc.state.sc.us]

Sent: Tuesday, December 07, 2010 7:14 AM

To: Halpenny, Susan M

Subject: clearance delay

Good morning Susan,

It has been a month since the FDA has chosen to delay delivery of a package sent from England to the South Carolina Department of Corrections. From our last conversation I understand there is a discussion regarding "jurisdiction" between the FDA and the DEA. If it does not appear that there will be a solution to this stalemate in the near future (think next 24 hours) can you direct me to someone who might be able to help expedite a decision?

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

From: Dixon, Ruth P
Sent: Thursday, December 09, 2010 2:24 PM
To: Veneziano, Domenic J.
Cc: Halpenny, Susan M
Subject: FW: Letter to Ms. Dixon

Attachments: Letter to Ms. Dixon0001.pdf

Good day Domenic,

Before I had the opportunity to return the call to the Undersecretary I received this message with the enclosed letter. Mr. McAuliffe also followed up with a phone call...they will be trying to call the Commissioner's office and you via the general phone numbers since they are receiving significant pressure from the Governor's office.

Ruth P. Dixon

Supervisory Investigator
New Orleans District
Import Operations

From: Kernan, Scott@CDCR [mailto:Scott.Kernan@cdcr.ca.gov]
Sent: Thursday, December 09, 2010 2:03 PM
To: Dixon, Ruth P
Cc: McAuliffe, John@CDCR; Rice, Benjamin@CDCR
Subject: FW: Letter to Ms. Dixon

Ms. Dixon,

Thank you for working with Mr. McAuliffe on obtaining FDA approval for the delivery of Sodium thiopental to California. Please find attached a letter detailing our legal procurement of the drug and our urgent interest in obtaining the shipment as soon as possible. Your immediate attention to this matter is greatly appreciated.

Please feel free to contact me should you have any questions. (916) 801-4358.

Sincerely,

Scott Kernan
Undersecretary
California Department of Corrections
And Rehabilitation

From: Gaddi, Kathy@CDCR
Sent: Thursday, December 09, 2010 11:58 AM
To: Kernan, Scott@CDCR
Subject: Letter to Ms. Dixon

Ruth.Dixon@FDA.HHS.gov

Kathy Gaddi
Executive Assistant to Scott Kernan
Undersecretary, Operations
(916) 341-7015

From: Halpenny, Susan M
Sent: Thursday, December 09, 2010 1:38 PM
To: 'John Solomon'
Subject: RE: status
Good day Dr. Solomon,

I have asked for an update on the status of your shipment from our Center for Imports but unfortunately they do not have any updates to give me. I will continue to check on this daily.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

From: John Solomon [mailto:Solomon.John@doc.state.sc.us]
Sent: Thursday, December 09, 2010 6:51 AM
To: Halpenny, Susan M
Subject: status

Good morning Susan,

May we have a status report with particular attention as to why the FDA continues to intervene in this particular drug purchase? Also, the delay now borders on being excessive. Does anyone have any idea when a decision will be rendered to release the shipment? Thank you for continuing assistance.

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

From: Dixon, Ruth P
Sent: Thursday, December 09, 2010 2:24 PM
To: Veneziano, Domenic J.
Cc: Halpenny, Susan M
Subject: FW: Letter to Ms. Dixon

Attachments: Letter to Ms. Dixon0001.pdf

Good day Domenic,

Before I had the opportunity to return the call to the Undersecretary I received this message with the enclosed letter. Mr. McAuliffe also followed up with a phone call...they will be trying to call the Commissioner's office and you via the general phone numbers since they are receiving significant pressure from the Governor's office.

Ruth P. Dixon

Supervisory Investigator
New Orleans District
Import Operations

From: Kernan, Scott@CDCR [mailto:Scott.Kernan@cdcr.ca.gov]
Sent: Thursday, December 09, 2010 2:03 PM
To: Dixon, Ruth P
Cc: McAuliffe, John@CDCR; Rice, Benjamin@CDCR
Subject: FW: Letter to Ms. Dixon

Ms. Dixon,

Thank you for working with Mr. McAuliffe on obtaining FDA approval for the delivery of Sodium thiopental to California. Please find attached a letter detailing our legal procurement of the drug and our urgent interest in obtaining the shipment as soon as possible. Your immediate attention to this matter is greatly appreciated.

Please feel free to contact me should you have any questions. (916) 801-4358.

Sincerely,

Scott Kernan
Undersecretary
California Department of Corrections
And Rehabilitation

From: Gaddi, Kathy@CDCR
Sent: Thursday, December 09, 2010 11:58 AM
To: Kernan, Scott@CDCR
Subject: Letter to Ms. Dixon

Ruth.Dixon@FDA.HHS.gov

Kathy Gaddi
Executive Assistant to Scott Kernan
Undersecretary, Operations
(916) 341-7015

From: John Solomon [Solomon.John@doc.state.sc.us]

Sent: Thursday, December 09, 2010 6:51 AM

To: Halpenny, Susan M

Subject: status

Good morning Susan,

May we have a status report with particular attention as to why the FDA continues to intervene in this particular drug purchase? Also, the delay now borders on being excessive. Does anyone have any idea when a decision will be rendered to release the shipment? Thank you for continuing assistance.

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

From: McAuliffe, John@CDCR [John.McAuliffe@cdcr.ca.gov]
Sent: Monday, December 20, 2010 12:44 PM
To: Dixon, Ruth P
Cc: Kernan, Scott@CDCR
Subject: FW: Letter to Ms. Dixon

Attachments: Letter to Ms. Dixon0001.pdf

Ms. Dixon

Could you please update us on the approval of delivery of the Sodium Thiopental to the California Department of Corrections and Rehabilitation. Thank you in advance.

John McAuliffe

From: McAuliffe, John@CDCR
Sent: Thursday, December 09, 2010 12:10 PM
To: McCleave, Kelly@CDCR
Subject: FW: Letter to Ms. Dixon

FYI

From: Kernan, Scott@CDCR
Sent: Thursday, December 09, 2010 12:03 PM
To: Ruth.Dixon@FDA.HHS.gov
Cc: McAuliffe, John@CDCR; Rice, Benjamin@CDCR
Subject: FW: Letter to Ms. Dixon

Ms. Dixon,

Thank you for working with Mr. McAuliffe on obtaining FDA approval for the delivery of Sodium thiopental to California. Please find attached a letter detailing our legal procurement of the drug and our urgent interest in obtaining the shipment as soon as possible. Your immediate attention to this matter is greatly appreciated.

Please feel free to contact me should you have any questions. (916) 801-4358.

Sincerely,

Scott Kernan
Undersecretary
California Department of Corrections
And Rehabilitation

From: Gaddi, Kathy@CDCR
Sent: Thursday, December 09, 2010 11:58 AM
To: Kernan, Scott@CDCR
Subject: Letter to Ms. Dixon

Ruth.Dixon@FDA.HHS.gov

Kathy Gaddi
Executive Assistant to Scott Kernan

Undersecretary, Operations
(916) 341-7015

From: John Solomon [Solomon.John@doc.state.sc.us]

Sent: Monday, December 20, 2010 9:29 AM

To: Halpenny, Susan M

Cc: David Tatarsky

Subject: Delay of Shipment

Good morning Susan,

The FDA imposed delay is an increasing concern to us. Is there anyone who can give us a reasonable explanation for the FDA's decision to stop the shipment to South Carolina? For the FDA to stop the shipment and then refuse to communicate the reason for its decision is unconscionable. Your assistance with this matter is appreciated.

John

Copy to David Tatarsky – General Counsel for the Department of Corrections

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

From: Halpenny, Susan M
Sent: Monday, December 20, 2010 10:25 AM
To: 'John Solomon'
Cc: David Tatarsky
Subject: RE: Delay of Shipment
Good day,

I have not heard anything from our Director of Import Operations and Policy at this time. If you would like to follow up with him, our Director is Domenic Veneziano and his phone number is (301) 594-3849. You can also contact the office of our FDA commissioner, Margaret Hamburg at (301) 796-5000.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

From: John Solomon [mailto:Solomon.John@doc.state.sc.us]
Sent: Monday, December 20, 2010 9:29 AM
To: Halpenny, Susan M
Cc: David Tatarsky
Subject: Delay of Shipment

Good morning Susan,

The FDA imposed delay is an increasing concern to us. Is there anyone who can give us a reasonable explanation for the FDA's decision to stop the shipment to South Carolina? For the FDA to stop the shipment and then refuse to communicate the reason for its decision is unconscionable. Your assistance with this matter is appreciated.

John

Copy to David Tatarsky – General Counsel for the Department of Corrections

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

Trepagnier, Timothy

From: Thomas, David
Sent: Monday, September 27, 2010 2:23 PM
To: Budweg, Greta L; Halpenny, Susan M
Cc: Dixon, Ruth P; Chan, Hoi-May (CBER); Samaan, Marian; Chung, Phap; Cowels, Allyson; Strickland, Evanguel; Solis, Daniel; 'DEAN, MICHAEL K'
Subject: RE: Lethal Injection Pharmacology

Greta:

Thank you for your courteous, informative and timely reply. I have advised the Broker, Arizona Customs Brokerage, Phoenix, AZ, Filer # 574, to transmit all entry documentation, regarding the above, prior to wheels-up, including AWB. I will then forward same to you and all principals.

As of this communication, the Filer has not received the paperwork to perform entry data for transmission to Custom's ACS system from the Automatic Broker Interface software.

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office

-----Original Message-----

From: Budweg, Greta L
Sent: Monday, September 27, 2010 10:02 AM
To: Halpenny, Susan M
Cc: Dixon, Ruth P; Thomas, David; Chan, Hoi-May (CBER); Samaan, Marian; Chung, Phap; Cowels, Allyson
Subject: RE: Lethal Injection Pharmacology

Susan,

We are running sweeps in CBP's ATS database to find this shipment prior to arrival. We've identified 2 similar shipments with our sweep with UPS-9066861-5 and 112-8992979-0. We'll keep you posted on anything we find.

Greta

Greta L. Budweg
Watch Commander
FDA/ORA/ORO/Prior Notice Center
866-521-2297 main phone
703-261-8439 phone
703-261-8625 fax
greta.budweg@fda.hhs.gov

-----Original Message-----

From: Halpenny, Susan M
Sent: Monday, September 27, 2010 12:44 PM
To: Thomas, David
Cc: Dixon, Ruth P; Budweg, Greta L
Subject: FW: Lethal Injection Pharmacology
Importance: High

Good day,

It would be helpful if you could provide Memphis the airway bill for this shipment. We can follow-up with the broker to see if/and when the shipment is being received. Also we would be able to track the shipment thru (b) (4). I appreciate any information you can provide.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

-----Original Message-----

From: Budweg, Greta L
Sent: Monday, September 27, 2010 11:31 AM
To: Schafer, Patricia
Cc: ORA SE NOL Import Supervisors; Taube, Anthony C
Subject: FW: Lethal Injection Pharmacology
Importance: High

Hi Pat,

I suggested to Dave Thomas that this information would be helpful to the Memphis entry reviewers. Dave indicated that no entry has been made at this time. I'll continue to pass on any information related to this shipment.

Greta

Greta L. Budweg
Watch Commander
FDA/ORA/ORO/Prior Notice Center
866-521-2297 main phone
703-261-8439 phone
703-261-8625 fax
greta.budweg@fda.hhs.gov

-----Original Message-----

From: Thomas, David
Sent: Monday, September 27, 2010 11:50 AM
To: Budweg, Greta L
Subject: FW: Lethal Injection Pharmacology
Importance: High

Dave Thomas
FDA Imports
Phoenix, AZ

-----Original Message-----

From: Thomas, David
Sent: Monday, September 27, 2010 8:23 AM
To: Taube, Anthony C
Cc: Strickland, Evanguel; Solis, Daniel; 'DEAN, MICHAEL K';
'CHARLES FLANAGAN'
Subject: Lethal Injection Pharmacology
Importance: High

Prior Notice Center Director, Anthony Taube:

RE: Lethal Injection pharmacology:

Sir:

I have an entry of 3 components of a lethal injection, 1) Thiopental, 2) Pancuronium, 3) Potassium Chloride departing London this afternoon, destination Memphis with Port of Entry 2605, Phoenix. As of this communication, no entry has been

made.

These pharmaceuticals are needed to carry out an execution here in Arizona, and are not for public consumption. Attached is Please find attached explanatory documentation and DEA registration for the Arizona Corrections facility.

Lastly, should I be advising anyone else?

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office

Charles:

We are in receipt of your communication and PDF attachments. I have CC'd my Supervisor, Mr. Strickland, and our Imports Director Mr. Solis for their review.

David Thomas, DCM
FDA Investigations
Phoenix, Office

-----Original Message-----

From: CHARLES FLANAGAN [mailto:CFLANAG@azcorrections.gov]
Sent: Friday, September 24, 2010 5:04 PM
To: Thomas, David
Subject: Pharmaceuticals from Dream Pharma, LTD. of London, England

Good Afternoon Mr. Thomas:

Thank you so much for your assistance with this matter. I have attached to this email a copy of the correspondence what will be shipped with the pharmaceuticals. It also includes the Department of Corrections' "Substance Control Registration Certificate". The second attachment is a list of the items that will be shipped to our facility; to include quantities purchased and the last attachment is the revised DEA Registration which includes certification for Schedule 2 drugs.

Once again, thank you again for your assistance. Should you require additional information, please do not hesitate to contact me. Here is my information:

Charles Flanagan
Deputy Director
Arizona Department of Corrections
1601 W. Jefferson - MC 445
Phoenix, Arizona 85007
(602) 542-3611 Office
(602) 377-5334 Cell
(602) 364-0601 Fax
cflanag@azcorrections.gov

ATTENTION SUSANMARK SANFORD, Governor
JON OZMINT, Director

October 29, 2010

United States Customs Department

SUBJECT: Thiopental Injection Purchase

Dear Customs Agent:

The South Carolina Department of Correction (SCDC) uses Thiopental Injection for capital punishment purposes. S. C. Code Ann. § 24-3-530 provides as follows:

Death by electrocution or lethal injection - "A person convicted of a capital crime and having imposed upon him the sentence of death shall suffer the penalty by electrocution or, at the election of the person, lethal injection under the direction of the Director of the Department of Corrections. The election for death by electrocution or lethal injection must be made in writing fourteen days before the execution date or it is waived. If the person waives the right of election, then the penalty must be administered by lethal injection."

The SCDC has been unable to locate this drug in the United States. In order to carry out its statutory obligation in capital punishment cases, SCDC has purchased Thiopental from a provider in Great Britain. Enclosed are the following drugs:

NAME/DESCRIPTION	QUANTITY
Thiopental Injection, powder for reconstitution, thiopental sodium, 500 mg vial packs of 25's	(b) (4)

Shipping Location:

South Carolina Department of Corrections
Kirkland Correctional Institution - Pharmacy
ATTN: Rose Mayer
4344 Broad River Road
Columbia, South Carolina 29210
Telephone: (803) 896-1995
US Drug Enforcement Agency Number (DEA): R50206765 Expires: 02/28/2011

I will be the point of contact for the purchase and can be reached by telephone: 001-803-896-1995 or by email: solomon.john@doc.state.sc.us.

Sincerely,

John P. Solomon, PhD, MBA
Director of Health Services

JP/spz

P.O. Box 21787 - 4444 Broad River Road - Columbia, SC 29221-1787 - Telephone (803) 896-8555

Trepagnier, Timothy

From: Bradford, Jacquelyn
Sent: Monday, September 27, 2010 4:14 PM
To: Dixon, Ruth P
Subject: FW: Lethal Injection Pharmacology

Importance: High

Attachments: Thomas, David - FDA Investigations (London Shipment) 2010-09-24.pdf; DOC092310_1.pdf; DEA Registration.pdf



Thomas, DOC092310_ DEA
- FDA Investi1.pdf (20 KB)ration.pdf (39

-----Original Message-----

From: Halpenny, Susan M
Sent: Monday, September 27, 2010 4:04 PM
To: Bradford, Jacquelyn
Subject: FW: Lethal Injection Pharmacology
Importance: High

Please use documentation as example for other shipment going to correction facility in ARK.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

-----Original Message-----

From: Budweg, Greta L
Sent: Monday, September 27, 2010 11:31 AM
To: Schafer, Patricia
Cc: ORA SE NOL Import Supervisors; Taube, Anthony C
Subject: FW: Lethal Injection Pharmacology
Importance: High

Hi Pat,

I suggested to Dave Thomas that this information would be helpful to the Memphis entry reviewers. Dave indicated that no entry has been made at this time. I'll continue to pass on any

information related to this shipment.

Greta

Greta L. Budweg
Watch Commander
FDA/ORA/ORO/Prior Notice Center
866-521-2297 main phone
703-261-8439 phone
703-261-8625 fax
greta.budweg@fda.hhs.gov

-----Original Message-----

From: Thomas, David
Sent: Monday, September 27, 2010 11:50 AM
To: Budweg, Greta L
Subject: FW: Lethal Injection Pharmacology
Importance: High

Dave Thomas
FDA Imports
Phoenix, AZ

-----Original Message-----

From: Thomas, David
Sent: Monday, September 27, 2010 8:23 AM
To: Taube, Anthony C
Cc: Strickland, Evanguel; Solis, Daniel; 'DEAN, MICHAEL K';
'CHARLES FLANAGAN'
Subject: Lethal Injection Pharmacology
Importance: High

Prior Notice Center Director, Anthony Taube:

RE: Lethal Injection pharmacology:

Sir:

I have an entry of 3 components of a lethal injection, 1)
Thiopental, 2) Pancuronium, 3) Potassium Chloride departing
London this afternoon, destination Memphis with Port of Entry

2605, Phoenix. As of this communication, no entry has been made.

These pharmaceuticals are needed to carry out an execution here in Arizona, and are not for public consumption. Attached is Please find attached explanatory documentation and DEA registration for the Arizona Corrections facility.

Lastly, should I be advising anyone else?

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office

Charles:

We are in receipt of your communication and PDF attachments. I have CC'd my Supervisor, Mr. Strickland, and our Imports Director Mr. Solis for their review.

David Thomas, DCM
FDA Investigations
Phoenix, Office

-----Original Message-----

From: CHARLES FLANAGAN [mailto:CFLANAG@azcorrections.gov]
Sent: Friday, September 24, 2010 5:04 PM
To: Thomas, David
Subject: Pharmaceuticals from Dream Pharma, LTD. of London, England

Good Afternoon Mr. Thomas:

Thank you so much for your assistance with this matter. I have attached to this email a copy of the correspondence what will be shipped with the pharmaceuticals. It also includes the Department of Corrections' "Substance Control Registration Certificate". The second attachment is a list of the items that will be shipped to our facility; to include quantities purchased and the last attachment is the revised DEA Registration which includes certification for Schedule 2 drugs.

Once again, thank you again for your assistance. Should you require additional information, please do not hesitate to contact me. Here is my information:

Charles Flanagan
Deputy Director
Arizona Department of Corrections
1601 W. Jefferson - MC 445
Phoenix, Arizona 85007
(602) 542-3611 Office
(602) 377-5334 Cell
(602) 364-0601 Fax
cflanag@azcorrections.gov

Arizona Department of Corrections



JANICE K. BREWER
GOVERNOR

1601 WEST JEFFERSON
PHOENIX, ARIZONA 85007
(602) 542-5497
www.azcorrections.gov



CHARLES L. RYAN
DIRECTOR

September 24 2010


David Thomas, DCM
FDA Investigations
Food and Drug Administration
Division of Import Operations and Policy
4605 East Elwood Street, Suite 402
Phoenix, Arizona 85040-1948

Dear Mr. Thomas:

Thank you for your professional assistance with the processing of this shipment. I am enclosing the original letter addressed to your agency and a copy of our Substance Control Registration Certificate.

Once again, thank you again for your assistance. Should you require additional information, please do not hesitate to contact me.

Sincerely,


Charles Flanagan
Deputy Director

cc: File

*Dave,
please do not hesitate to
contact me for any reason. I
greatly appreciate your assistance,
Charles*



JANICE K. BREWER
GOVERNOR

Arizona Department of Corrections

1601 WEST JEFFERSON
PHOENIX, ARIZONA 85007
(602) 542-5487
www.azcorrections.gov



CHARLES L. RYAN
DIRECTOR

September 24, 2010

David Thomas, DCM
FDA Investigations
Food and Drug Administration
Division of Import Operations and Policy
4605 East Elwood Street, Suite 402
Phoenix, Arizona 85040-1948

Re: Execution by Lethal Injection of Arizona Inmate
Jeffrey Timothy Landrigan #082157

Dear Mr. Thomas:


The purpose of this correspondence is to advise your agency of our intent to receive certain pharmaceutical products from Dream Pharma, Ltd. of London, England. We have placed the order with this company for the purpose of securing the necessary drugs for carrying out an execution warrant issued by the Arizona Supreme Court in the matter of State v. Jeffrey Timothy Landrigan, CR-90-0323 AP.

In order to proceed with the execution we must have the products ordered through Dream Pharma. Our DEA Registration number is: FA2203571 and it expires June 30, 2013. The execution is set by the court for October 26, 2010, and our agency is mandated to advise the court that it possesses the necessary chemicals for the lethal injection protocol as approved, no later than October 1, 2010.

Any steps your agency can take in attending to this shipment expeditiously would be of great assistance to our agency in its effort to abide by the court-ordered dates set by the court. Should your agency have any questions, do not hesitate to contact my office directly at (602) 542-5225 or after normal business hours through our command center at (602) 542-1212.

Thank you in advance for your professional assistance with the processing of this shipment.

Sincerely,



Charles L. Ryan
Director

cc: Charles Flanagan, Deputy Director
Robert Patton, Division Director, Offender Operations
Carson McWilliams, Warden, ASPC Florence

ARIZONA STATE PRISON - FLORENCE, CARSON
WARDEN
1305 BUTTE AVE.
P.O. BOX 629
FLORENCE, AZ 85232-0000-000



DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA2203571	06-30-2013	FEE EXEMPT
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
3,3N,4,5,	HOSPITAL/CLINIC	08-25-2010
ARIZONA STATE PRISON - FLORENCE, CARSON WARDEN 1305 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85232-0000		

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON D.C. 20537

This registration is only for use at Federal or State institutions.

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

Form DEA-223 (4/07)

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA2203571	06-30-2013	FEE EXEMPT
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
3,3N,4,5,	HOSPITAL/CLINIC	08-25-2010
ARIZONA STATE PRISON - FLORENCE, CARSON WARDEN 1305 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85232-0000		

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON D.C. 20537

This registration is only for use at Federal or State institutions.

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

DEA REGISTRATION NUMBER FA2203571	THIS REGISTRATION EXPIRES 06-30-2013	FEE PAID FEE EXEMPT
SCHEDULES 3.3N.4.5.	BUSINESS ACTIVITY HOSPITAL/CLINIC	ISSUE DATE 08-25-2010
ARIZONA STATE PRISON - FLORENCE, CARSON WARDEN 1305 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85232-0000		

**CONTROLLED SUBSTANCE/REGULATED CHEMICAL
REGISTRATION CERTIFICATE**
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON D.C. 20537

This registration is only for use at Federal or State institutions.

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

Form DEA-223/511 (4/07)

**REPORT
CHANGES
PROMPTLY**

**REQUESTING MODIFICATIONS TO YOUR
REGISTRATION CERTIFICATE**

To request a change to your registered name, address, the drug schedule or the drug codes you handle, please

1. visit our web site at deaddiversion.usdoj.gov - or
2. call our customer Service Center at 1-(800) 882-9539 - or
3. submit your change(s) in writing to:

Drug Enforcement Administration
P.O. Box 28083
Washington, DC 20083

See Title 21 Code of Federal Regulations, Section 1301.51 for complete instructions.

You have been registered to handle the following chemical/drug codes:

Fax

To:	Matt Alavi	From:	Karen Ingram, Contracts Manager
Company/ Institution:	Dream Pharma, LTd 176 Horn Lane Acton, London W3 6PJ	Pages:	1
Fax:	44 208-992-7001	Date:	9/23/10
Phone:	44-208-992-7000	Re:	Urgent Order USA

☐ **Urgent** ☐ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

● **Comments:** THIS ORDER MUST BE RECEIVED BY THE DEPARTMENT NO LATER THAN OCTOBER 1, 2010.

Based on previous conversations between the Arizona Department of Corrections, we are placing the following order:

1. **THIOPENTAL INJECTION** (powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's)
Item Cost: (b) (4) (pounds Sterling)
Quantity: (b) (4)
2. **PANCURONIUM INJECTION** (pancuronium bromide 2 mg/ml, 2-ml amp)
Item Cost: Awaiting cost from Vendor – please confirm the price once obtained
Quantity: (b) (4)
3. **POTASSIUM CHLORIDE** (1.5gm, 10ml, injection packs of 10)
Item Cost: (b) (4)
Quantity: (b) (4)

Payment for this order will be by credit card, to be provided via telephone. Please contact me for additional information.

Karen Ingram
p: 602-364-3791

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA2203571	06-30-2013	Exempt
SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3 3N,4,5	HOSPITAL/CLINIC	08-25-2010
ARIZONA STATE PRISON - FLORENCE, CARSON A., WARDEN 1305 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85232 0000		

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

This registration is only for use at Federal or State institutions.

Sections 304 and 1008 (21 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IS NOT VALID AFTER THE EXPIRATION DATE.

Form DEA-223 (05/04)

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA2203571	06-30-2013	Exempt
SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3 3N,4,5	HOSPITAL/CLINIC	08-25-2010
ARIZONA STATE PRISON - FLORENCE, CARSON A., WARDEN 1305 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85232 0000		

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.

This registration is only for use at Federal or State institutions.

Sections 304 and 1008 (21 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

OFFICE OF THE SECRETARY

P.O. Box 942883
Sacramento, CA 94283-0001



December 9, 2010

Ms. Ruth Dixon
Department of Health and Human Services
Food and Drug Administration

Dear Ms. Dixon:

Since 1993, California law has authorized capital punishment by lethal injection pursuant to Penal Code Section 3604. The law states the punishment of death shall be inflicted by the administration of an intravenous injection of substances in a lethal quantity sufficient to cause death. On May 1, 2009, the California Department of Corrections and Rehabilitation (CDCR) promulgated regulations setting forth the requirements for administering capital punishment by lethal injection pursuant to Administrative Procedure Act. Those regulations became effective on August 29, 2010. The regulations provide for the use of three chemicals; sodium thiopental, pancuronium bromide, and potassium chloride.

There is a national shortage of sodium thiopental. California, like many other states, has been actively seeking supplies of the sodium thiopental for future executions. California's supply of sodium thiopental expired on October 1, 2010. On November 22, 2010, CDCR notified the United States District Court for the Northern District of California that it had ordered (b) (4) of sodium thiopental that expires in 2014 from a manufacturer based in England (FDA # 112-99-38358-2). CDCR expected to receive the sodium thiopental during the week of November 29, 2010. Although CDCR followed all proper procedures and the Drug Enforcement Agency and United States Customs has approved the shipment, this shipment is currently be held by your office.

Per your conversation with John McAuliffe, we are asking for the immediate release and shipment of the (b) (4) of sodium thiopental. If you have any questions, concerns or any changes arise, please contact me at (916) 323-6001 or Mr. McAuliffe at (707) 480-6766.

Sincerely,

BENJAMIN T. RICE
General Counsel

cc: John McAuliffe



DEPARTMENT OF HEALTH AND HUMAN SERVICE

Food and Drug Administration
New Orleans District
Import Operations
959 Ridgeway Loop, Suite 100
Memphis, Tn. 38120

Telephone: (901) 333-3520
FAX: (901) 333-3579

January 7, 2011

UNITED PARCEL SERVICE
Delivery Signature Requested

Benjamin Rice, Chief Counsel
Office of Legal Affairs
California Department of Corrections & Rehabilitation
1515 S Street, Suite 502 S
Sacramento, California 95811

RE: Entry Number 112-9938358-2

Dear Mr. Rice:

This letter provides the status of Entry Number 112-9938358-2, consisting of (b) (4) vial packets, each vial containing 500 mg of Thiopental Sodium. FDA received documentation for this shipment and verified it is destined for a state correctional facility.

FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity or any other characteristics.

Sincerely,

Patricia K. Schafer
Acting District Director
New Orleans District Office

From: Dixon, Ruth P
Sent: Friday, January 07, 2011 3:43 PM
To: 'Rice, Benjamin@CDCR'
Cc: 'McAuliffe, John@CDCR'; 'Kernan, Scott@CDCR'
Subject: RE: Letter to Ms. Dixon

Attachments: FDA Letter 010711.pdf
[Good afternoon,](#)

[Enclosed is the FDA letter regarding the FDA Release of entry 112-9938358-2.](#)

Ruth P. Dixon
Supervisory Investigator
New Orleans District
Import Operations

From: Kernan, Scott@CDCR [mailto:Scott.Kernan@cdcr.ca.gov]
Sent: Thursday, December 09, 2010 2:03 PM
To: Dixon, Ruth P
Cc: McAuliffe, John@CDCR; Rice, Benjamin@CDCR
Subject: FW: Letter to Ms. Dixon

Ms. Dixon,

Thank you for working with Mr. McAuliffe on obtaining FDA approval for the delivery of Sodium thiopental to California. Please find attached a letter detailing our legal procurement of the drug and our urgent interest in obtaining the shipment as soon as possible. Your immediate attention to this matter is greatly appreciated.

Please feel free to contact me should you have any questions. (916) 801-4358.

Sincerely,

Scott Kernan
Undersecretary
California Department of Corrections

FDA_08.18.11_000036

And Rehabilitation

From: Gaddi, Kathy@CDCR
Sent: Thursday, December 09, 2010 11:58 AM
To: Kernan, Scott@CDCR
Subject: Letter to Ms. Dixon

Ruth.Dixon@FDA.HHS.gov

Kathy Gaddi
Executive Assistant to Scott Kernan
Undersecretary, Operations
(916) 341-7015

United States Food and Drug Administration

New Orleans District Office

Notice of FDA Action

Entry Number: 112-7818637-8

Notice Number: 3

August 13, 2010

Importer:

(b) (4)

>

<

Port of Entry: 2095, FedEx - Memphis, Memphis, TN

Carrier: (b) (4)

Date Received: June 28, 2010

Arrival Date: June 28, 2010

Filer of Record: FEDEX Trade Networks Transport and Brokerage, Memphis, TN 38125

Consignee: (b) (4)

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
* 001/001	688760417429/THIOPENTAL 500MG	(b) (4)	Released after Detention 08-12-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 112-7818637-8. Any status changes are reflected in the Line summary and line detail sections.

LINES RELEASED AFTER DETENTION

Line ACS/FDA	Product Description
001/001	688760417429/THIOPENTAL 500MG

Rebecca A. Asente, Compliance Officer
(Region/District)
U.S. Food and Drug Administration
6600 Plaza Drive, Suite 400
New Orleans, LA 70127

(504) 219-8818 ext. 104
(504) 219-8813 (FAX)
REBECCA.ASENTE@FDA.HHS.GOV

These products are released. This notice does not constitute assurance that the product released complies with all

112-7818637-8

Notice of FDA Action
Entry Number: 112-7818637-8

Notice Number: 3
Page: 2

provisions of the Food, Drug, and Cosmetic Act, or other related Acts, and does not preclude action should the product later be found violative.

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: LPW

United States Food and Drug Administration

New Orleans District Office

Notice of FDA Action

Entry Number: 112-7818637-8

Notice Number: 2

July 16, 2010

Consignee:

(b) (4)

>

<

Port of Entry: (b) (4) Memphis, TN

Carrier: (b) (4)

Date Received: June 28, 2010

Arrival Date: June 28, 2010

Filer of Record: FEDEX Trade Networks Transport and Brokerage, Memphis, TN 38125

Importer of Record: (b) (4)

HOLD DESIGNATED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
* 001/001	688760417429/THIOPENTAL 500MG	(b) (4)	Detained 07-15-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

FDA will not request redelivery for examination or sampling, if the products not released by FDA are moved, following USCS conditional release to a location within the local metropolitan area or to a location approved by the FDA office at the number below.

All products in this entry not listed above may proceed without FDA examination. This notice does not constitute assurance the products involved comply with provisions of the Food, Drug, and Cosmetic Act or other related acts, and does not preclude action should the products later be found violative.

DETENTION

The following products are subject to refusal pursuant to the Federal Food Drug and Cosmetic Act (FD&CA), Public Health Service Act (PHSA), or other related acts in that they appear to be adulterated, misbranded or otherwise in violation as indicated below:

Line ACS/FDA	Product Description	Respond By
001/001	688760417429/THIOPENTAL	August 4, 2010

Notice of FDA Action
Entry Number: 112-7818637-8

Notice Number 2
Page: 2

500MG

FD&CA Section 502(o), 801(a)(3); MISBRANDING

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k). Mfr not Listed or Registered with FDA.

Please direct your response to:

Rebecca A. Asente, Compliance Officer
(Region/District)
U.S. Food and Drug Administration
6600 Plaza Drive, Suite 400
New Orleans, LA 70127

(504) 219-8818 ext. 104
(504) 219-8813 (FAX)
REBECCA.ASENTE@FDA.HHS.GOV

You have the right to provide oral or written testimony, to the Food & Drug Administration, regarding the admissibility of the article(s) or the manner in which the article(s) can be brought into compliance. This testimony must be provided to FDA on or before the dates shown above.

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: MJS

Spikes, Michael

From: Asente, Rebecca
Sent: Wednesday, June 30, 2010 3:23 PM
To: Spikes, Michael
Cc: Schafer, Patricia
Subject: Import Entries Update 2nd for Today

Hi Michael,

These are the last of the entries I received via Mark yesterday.

Released:

LEX
completed
7-1-2010

Created an LEX for:
112 7818637-8

I will put in interoffice mail the paperwork corresponding with the released entries.

Now, I will start working on the DTRs you just sent me today. I will send future updates to "reply all" from the emails you send w/the DTR hyperlinks.

Good to talk with you, R

Rebecca A. Asente, M.S., R.D., Compliance Officer

U.S. FDA, New Orleans District, Metairie Resident Post, Metairie Center, Suite 410, 2424 Edenborn Avenue, Metairie, LA 70001

(504) 219-8818 ext. 104; fax (504) 219-8813

This e-mail message is intended for the exclusive use of the recipient(s) named above. The contents of this message are mine personally and do not necessarily reflect any position of the Government or the Food and Drug Administration. It may contain information that is protected, privileged, or confidential, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. If you are not the intended recipient, any dissemination, distribution or copying is strictly prohibited. If you think you have received this e-mail in error, please contact the sender immediately at rebecca.asente@fda.hhs.gov.

Detained
RSA
7-15-2010

✓

DEPARTMENT OF THE TREASURY
UNITED STATES CUSTOMS SERVICEForm Approved
OMB No. 1515-0069

ENTRY/IMMEDIATE DELIVERY

ABI CERTIFIED

FEDEX TRADE NETWORKS
TRANSPORT & BROKERAGE, INC.
TEL: (901) 752-3000

AIR EXPRESS

19 CFR 142.3, 142.16, 142.22, 142.24

1. ARRIVAL DATE 062810	2. ELECTED ENTRY DATE	3. ENTRY TYPE CODE/NAME 11	4. ENTRY NUMBER 112-7818637-8
5. PORT 2095	6. SINGLE TRANS. BOND	7. BROKER/IMPORTER FILE NUMBER (b) (4)	
	8. CONSIGNEE NUMBER NAME/ADDRESS		9. IMPORTER NUMBER (b) (4)
10. ULTIMATE CONSIGNEE NAME (b) (4)		11. IMPORTER OF RECORD NAME (b) (4)	
12. CARRIER CODE (b) (4)	13. VOYAGE/FLIGHT/TRIP (b) (4)	14. LOCATION OF GOODS-CODE(S)/NAME(S) (b) (4)	
15. VESSEL CODE/NAME			
16. U.S. PORT OF UNLADING 2095	17. MANIFEST NUMBER	18. G.O. NUMBER	19. TOTAL VALUE (b) (4)
20. DESCRIPTION OF MERCHANDISE PHARMACEUTICALS NOT RESTRICTED			
21. 17/BL/AVB CODE M H	22. 17/BL/AVB NO. TOTAL (b) (4)	23. MANIFEST QUANTITY (b) (4)	24. H.S. NUMBER 3004.90.9190
			25. COUNTRY OF ORIGIN GB
			26. MANUFACTURER ID. GBDREPHA176LON

27. CERTIFICATION

I hereby make application for entry/immediate delivery. I certify that the above information is accurate, the bond is sufficient, valid, and current, and that all requirements of 19 CFR Part 142 have been met.

SIGNATURE OF APPLICANT

(b) (6)

PHONE NO.

(b) (4)

DATE

06/28/10

29. BROKER OR OTHER GOVT. AGENCY USE

28. CUSTOMS USE ONLY

☐ OTHER AGENCY ACTION REQUIRED, NAMELY:☐ CUSTOMS EXAMINATION REQUIRED.☐ ENTRY REJECTED, BECAUSE:DELIVERY
AUTHORIZED:

SIGNATURE

DATE

→ Compounding

25X - for pharm
Compdng
only?

NO Det 7/15

Paperwork Reduction Act Notice: This information is needed to determine the admissibility of imports into the United States and to provide the necessary information for the examination of the cargo and to establish the liability for payment of duties and taxes. Your response is necessary.

06/28/10 19:45:47 ECO

Released 8/12/10

Customs Form 3481 (010189)
FDA-08-18-11-000043

Dream Pharma Ltd.

176 Horn Lane, Acton, London, W3 6PJ
Tel: 020 8992 7000 Fax: 020 8992 7001
E-Mail: info@dreampharma.com

Invoice Details

Number: 2583INV.

Date: 24-06-2010

Address:

(b) (4)

Delivery Address:

(b) (4)

VAT no:

Purchase Order:

Currency: GBP - Pounds sterling

Heading: PHARMACEUTICALS


Order Details

Name/Description	Quantity	Price	Total
Thiopental Injection , powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's Batch No: AS3393 EXP: 02/14	(b) (4)	(b) (4)	84.22
Admin fee for orders below £250	1	15	15

Statement Details

Goods Total: 99.22	Subtotal: 99.22
Discount (%): 0	VAT (World Zero): 0.00
Delivery: 0	Previous Balance: 0
Insurance: 0	Total: 99.22 GBP - Pounds sterling
	Payment Method: Prepayment Thank You

Shipping Details

Packing: (b) (4)	Gross Weight (Kg): (b) (4) Net Weight (Kg): (b) (4)
Tariff: 30049099	Carrier: (b) (4)
Declarations: We certify that this invoice is true and correct.	Matt Alavi, for Dream Pharma Ltd.  DREAM PHARMA 176 Horn Lane Acton, London W3 6PJ Tel: 020-8992-7000 Fax: 020-8992-7001

Damage, shortage or leakage must be notified in writing to ourselves within 3 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale. E&OE

Company Registration Number: (b) (4) /AT No. (b) (4)
Director: M. Alavi

ENTRY NUMBER: 112 7818637 8

AWB/BL NBR : (b) (4)

INVOICE #

LINE CONSOL. WORKSHEET

PAGE: 1

06/28/2010

07:49 PM

ITEMS MARKED 1 C/O- GB
TARIFF # 3004.90.9190

LINE VALUE- GBP

QTY 1: KG

(b) (4)

84.22

**

(b) (4)

**

84.22

84.22

*** END OF REPORT ***

ENTRY NUMBER: 112 7818637 8

AWB/BL NBR : (b) (4) INVOICE #

SHIPPER : DREAM PHARMA LTD

ITEM MARKED REFERENCE

PAGE: 1

06/28/2010

07:49 PM

INVOICE LINE#	ITEM MARK	TARIFF NUMBER	COUNTRY OF ORIG.	RATE OF DUTY
------------------	--------------	------------------	---------------------	--------------

VALUE-GBP

1	(b) (4)	3004.90.9190	GB	
---	---------	--------------	----	--

Q:

(b) (4) KG
84.22

*** END OF REPORT ***

FDA_08.18.11_000046

(b) (4) Manifest report

SHP DT 28 JUN 2010 SNDR# (b) (4) METER THERMAL ☒ RECEIPT 260722620 Routing code

(b) (4)

NAME Matt Alavi

COMP Dream Pharma Ltd.

ADD1 178 Horn Lane

ADD2

CITY ACTON, LONDON

ST/PV CNTRY GB POSTAL W38PJ

REF Pharmaceuticals Not Restricted

PKGS (b) (4) WEIGHT (b) (4)

K/L K

DIM WEIGHT

1 K/L K

DESC PHARMACEUTICALS NOT RESTRICTED

HS CD
30049099

COM
GB

CUST VAL

EXP DT
0

EXP LTC

(b) (4)

(b) (4)

LOCATION MEM

NEW INTERNATIONAL AIRBILL ENTRY

ENT# 112-7818637-8

(b) (4)

NAME MATT ALAVI

COMP DREAM PHARMA LTD.

ADD1 176 HORN LANE

ADD2

CITY ACTON, LONDON

ST/PV CENTRY GB POSTAL W36PJ

(b) (4)

(b) (4)

PKGS K/L
(b) (4) K

WEIGHT COM CURR
(b) (4) GB UKL

CARR VAL CUSTOMS VAL EX LIC HDLG UNITS
99.22

DESC: PHARMACEUTICALS NOT RESTRICTED

From: Boulmay, Christopher
Sent: Tuesday, November 30, 2010 4:00 PM
To: 'McAuliffe, John@CDCR'
Cc: Kernan, Scott@CDCR; Halpenny, Susan M; Dixon, Ruth P
Subject: RE: FDA entry item # 112-99-38358-2
John,

This entry is currently under review by our DIOP branch. (b) (5)
If you need additional information you can call Supervisor Susan Halpenny at 901-333-3521 or Supervisor Ruth Dixon at 901-333-3522. I am not authorized to make an admissibility decision on the entry.

Thank you,

Christopher Boulmay

Consumer Safety Officer
US Food & Drug Administration
NOL-DO: Memphis R.P.
Phone: (901) 333-3528
Fax: (901) 333-3577

From: McAuliffe, John@CDCR [mailto:John.McAuliffe@cdcr.ca.gov]
Sent: Tuesday, November 30, 2010 3:37 PM
To: Boulmay, Christopher
Cc: Kernan, Scott@CDCR
Subject: FDA entry item # 112-99-38358-2

Mr. Boulmay

I am inquiring into the shipment (# 112-99-38358-2) that is currently awaiting FDA approval. The shipment is to be sent to (b) (4)
(b) (6) is the (b) (4) contact person. I also called your phone number 901-333-3528 and left a message. If you could please return my call I would like to know the timeline for release. Thank you in advance.

John McAuliffe
California Department of Corrections and Rehabilitation

United States Food and Drug Administration

New Orleans District Office

Notice of FDA Action

Entry Number: 112-8992979-0

Notice Number: 2
September 28, 2010

Importer:

(b) (4)

> Port of Entry: 2095, FedEx - Memphis, Memphis, TN

Carrier: (b) (4)

Date Received: September 20, 2010

Arrival Date: September 17, 2010

Filer of Record: FEDEX Trade Networks Transport and Brokerage, Memphis, TN 38125

Consignee: Arkansas Department Of Correctio, Pine Bluff, AR 71602-9411

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
* 001/001	688760418241/THIOPENTAL SODIUM	(b) (4)	Released after Detention 09-27-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 112-8992979-0. Any status changes are reflected in the Line summary and line detail sections.

DETENTION

The following products are subject to refusal pursuant to the Federal Food Drug and Cosmetic Act (FD&CA), Public Health Service Act (PHSA), or other related acts in that they appear to be adulterated, misbranded or otherwise in violation as indicated below:

Line ACS/FDA	Product Description	Respond By
001/001	688760418241/THIOPENTAL SODIUM	November 1, 2010

FD&CA Section 505(a), 801(a)(3); UNAPPROVED NEW DRUG

The article appears to be a new drug without an approved new drug application. Unapproved drug w/o written

112-8992979-0

DEPARTMENT OF THE TREASURY
UNITED STATES CUSTOMS SERVICEForm Approved
OMB No. 1515-0069

ENTRY/IMMEDIATE DELIVERY

ABI CERTIFIED

FEDEX TRADE NETWORKS
TRANSPORT & BROKERAGE, INC.

AIR EXPRESS

TEL: (901) 752-3000

19 CFR 142.3, 142.16, 142.22, 142.24

1. ARRIVAL DATE 091710	2. ELECTED ENTRY DATE	3. ENTRY TYPE CODE/NAME 11	4. ENTRY NUMBER 112-8992979-0
5. PORT 2095	6. SINGLE TRANS. BOND	7. BROKER/IMPORTER FILE NUMBER (b) (4)	
	8. CONSIGNEE NUMBER NAME/ADDRESS	9. IMPORTER NUMBER (b) (4)	
10. ULTIMATE CONSIGNEE NAME ARKANSAS DEPARTMENT OF C 6814 PRINCETON PIKE PINE BLUFF AR		11. IMPORTER OF RECORD NAME (b) (4)	
12. CARRIER CODE (b) (4)	13. VOYAGE/FLIGHT/TRIP (b) (4)	14. LOCATION OF GOODS CODE(S)/NAME(S) (b) (4)	
15. VESSEL CODE/NAME			
16. U.S. PORT OF UNLADING 2095	17. MANIFEST NUMBER	18. G.O. NUMBER	19. TOTAL VALUE 893
20. DESCRIPTION OF MERCHANDISE PHARMACEUTICALS/THIOPENTAL			
21. IT/BL/AWB CODE M H	22. IT/BL/AWB NO. TOTAL (b) (4)	23. MANIFEST QUANTITY (b) (4)	24. H.S. NUMBER 3004.90.9140
			25. COUNTRY OF ORIGIN GB
			26. MANUFACTURER ID. GBDREPHA176LON

27. CERTIFICATION

I hereby make application for entry/immediate delivery. I certify that the above information is accurate, the bond is sufficient, valid, and current, and that all requirements of 19 CFR Part 142 have been met.

SIGNATURE OF APPLICANT

(b) (6)

PHONE NO.

(b) (4)

DATE

09/20/10

29. BROKER OR OTHER GOVT. AGENCY USE

28. CUSTOMS USE ONLY

☐ OTHER AGENCY ACTION REQUIRED, NAMELY:

☐ CUSTOMS EXAMINATION REQUIRED.

☐ ENTRY REJECTED, BECAUSE:
DELIVERY
AUTHORIZED:

SIGNATURE

DATE

DTR - AAP/REG

FDA_08.18.11_000051

Dream Pharma Ltd.

176 Horn Lane, Acton, London, W3 6PJ
Tel: 020 8992 7000 Fax: 020 8992 7001
E-Mail: info@dreampharma.com

Invoice Details**Number:** 2668INV**Date:** 17-09-2010**Address:**

Arkansas Department of Correction
Central Administration Office
6814 Princeton Pike
Pine Bluff, AR 71602-9411
Fedex: 4512-1458-6
Tel: 870-550 - 7307

Delivery Address:

Arkansas Department of Correction
Att: Wendy Kelley, Deputy Director
Central Administration Office
6814 Princeton Pike
Pine Bluff, AR 71602-9411
Fedex: 4512-1458-6
870-550 - 7307

VAT no:**Currency:** GBP - Pounds sterling**Purchase Order:****Heading:** PHARMACEUTICALS NOT RESTRICTED**Order Details**

Name/Description	Quantity	Price	Total
Thiopental Injection , powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's Batch No: AWW6022 EXP: 05/14	(b) (4)		590.25

Statement Details

Goods Total: 590.25	Subtotal: 590.25
Discount (%): 0	VAT (World Zero): 0.00
Delivery: 0	Previous Balance: 0
Insurance: 0	Total: 590.25 GBP - Pounds sterling
	Payment Method: Prepayment Thank You

Shipping Details

Packing: (b) (4)	Gross Weight (Kg): (b) (4)
Tariff: 30049099	Net Weight (Kg): (b) (4)
Carrier: (b) (4)	Carrier: (b) (4)
Declarations: We certify that this invoice is true and correct.	Matt Alavi, Dream Pharma Ltd 176 Horn Lane Acton, London W3 6PJ Tel: 020-8992-7000 Fax: 020-8992-7001

Damage, shortage or leakage must be notified in writing to ourselves within 3 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale. E&OE

Company Registration Number: 4637884 VAT No. GB805-5541-41
Director: M. Alavi

Page 1 of 1

ENTRY NUMBER: 112 8992979 0

AWB/BL NBR : (b) (4)

INVOICE #
LINE CONSOL. WORKSHEET

PAGE: 1

09/20/2010

05:55 PM

ITEMS MARKED 1 C/O- GB
TARIFF # 3004.90.9140
QTY 1: KG
(b) (4)

LINE VALUE- GBP

590.25

**

**

590.25

590.25

*** END OF REPORT ***

FDA_08.18.11_000053

ENTRY NUMBER: 112 8992979 0

AWB/BL NBR : (b) (4) INVOICE #

SHIPPER : DREAM PHARMA LTD

PAGE: 1

09/20/2010

05:55 PM

ITEM MARKED REFERENCE

INVOICE LINE#	ITEM MARK	TARIFF NUMBER	COUNTRY OF ORIG.	RATE OF DUTY
------------------	--------------	------------------	---------------------	--------------

VALUE-GBP

1	(b) (4)	3004.90.9140	GB	
---	---------	--------------	----	--

Q: (b) (4) KG
590.25

*** END OF REPORT ***

FDA_08.18.11_000054

**Archimedes Pharma UK Ltd**250 South Oak Way, Green Park, Reading, RG2 6UG,
UK

Telephone: +44 (0)118 931 5050

Fax: +44 (0)118 931 5056

WWW: <http://www.archimedespharma.com>

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

C/O Mfg info
Archimedes

A II

(b) (7)(C)

Summary of Product Characteristics last updated on the eMC: 05/05/2004

Thiopental injection

(b) (4)

tracking to

6887 6041 8241

1. NAME OF THE MEDICINAL PRODUCT

Thiopental Injection BP

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Thiopental Sodium BP 500mg

3. PHARMACEUTICAL FORM

Freeze-dried powder for solution for injection in a vial.

4. CLINICAL PARTICULARS**4.1 Therapeutic Indications**

1. Thiopental is used for the induction of general anaesthesia and is also used as an adjunct to provide hypnosis during balanced anaesthesia with other anaesthetic agents, including analgesics and muscle relaxants.

2. Thiopental is also used as an adjunct for control of convulsive disorders of various aetiology, including those caused by local anaesthetics.

3. Thiopental has now been used to reduce the intracranial pressure in patients with increased intracranial pressure, if controlled ventilation is provided.

4.2 Posology and method of administration

Intravenous injection.

Thiopental Injection BP is administered intravenously normally as a 2.5% w/v (500mg in 20ml) solution. On occasions it may be administered as a 5% w/v solution (500mg in 10ml).

The intravenous injection preparation should be used after reconstitution of the sterile powder with Water for injections, usually to produce a 2.5% w/v solution and this should be discarded after seven hours.

Use in anaesthesia

Normal dosage for the induction of anaesthesia is 100mg to 150mg injected over 10 to 15 seconds. If necessary a repeat dose of 100mg to 150mg may be given after one minute. No fixed dosage recommendations for the intravenous injection can be given, since the dosage will need to be carefully adjusted according to the patient's response. Factors such as age, sex, and weight of the patient should be taken into consideration. Thiopental sodium reaches effective concentrations in the brain within 30 seconds and anaesthesia is normally produced within one minute of an intravenous dose.

Adult

100mg to 150mg intravenously over 10 to 15 seconds, normally as a 2.5% w/v solution.

A repeat dose of 100mg to 150mg may be given after one minute.

The intravenous injection should be given slowly and the amounts given titrated against the patient's response to minimise the risk of respiratory depression or the possibility of overdosage. The average dose for an adult of 70kg is roughly 200mg to 300mg (8mls to 12mls of a 2.5% w/v solution) with a maximum of 500mg.

Children

2 to 7mg/kg bodyweight, intravenously over 10 to 15 seconds, normally as a 2.5% w/v solution. A repeat dose of 2 to 7mg/kg may be given after one minute. The dose is 2 to 7mg/kg based on the patient's response. The dose for children should not exceed 7mg/kg.

Elderly

Smaller adult doses are advisable.

Use in convulsive states

75mg to 125mg (3mls to 5mls of a 2.5% w/v solution) should be given as soon as possible after the convulsion begins. Further doses may be required to control convulsions following the use of a local anaesthetic. Other regimens, such as the use of intravenous or rectal diazepam, may be used to control convulsive states.

Use in neurological patients with raised intracranial pressure

Intermittent bolus injections of 1.5 to 3mg/kg of bodyweight may be given to reduce elevations of intracranial pressure if controlled ventilation is provided.

4.3 Contraindications

Thiopental is contraindicated in respiratory obstruction, acute asthma, severe shock and dystrophia myotonica. Administration of any barbiturate is contraindicated in porphyria.

Care should also be exercised with severe cardiovascular diseases, severe respiratory diseases and hypertension of various aetiology.

Patients with hypersensitivity reactions to barbiturates.

4.4 Special warnings and precautions for use

Special care is needed in administering thiopental to patients with the following conditions:- hypovolaemia, severe haemorrhage, burns, dehydration, severe anaemia, cardiovascular disease, status asthmaticus, severe liver disease, myasthenia gravis and muscular dystrophies, adrenocortical insufficiency (even when controlled by cortisone), cachexia and severe toxemia, raised intracranial pressure, raised blood urea, raised plasma potassium, metabolic disorders e.g. thyrotoxicosis, myxoedema, diabetes.

Thiopental may precipitate acute circulatory failure in patients with cardiovascular disease, particularly constrictive pericarditis.

Thiopental can cause respiratory depression and a reduction in cardiac output.

Headache is also reported with the use of barbiturate anaesthetics.

Reduced doses are recommended in shock, dehydration, severe anaemia, hyperkalaemia, toxemia, myxoedema or other metabolic disorders. Thiopental sodium is metabolised primarily by the liver so doses should be reduced in patients with hepatic impairment. Reduced doses are also indicated in the elderly and in

patients who have been premedicated with narcotic analgesics.

Thiopental has been shown to interact with sulphafurazole. Reduced initial doses may be required to achieve adequate anaesthesia, but repeat doses may also be necessary to maintain anaesthesia.

Increased doses may be necessary in patients who have either an habituation or addiction to alcohol or drugs of abuse. Under these circumstances it is recommended that supplementary analgesic agents are used.

Accidental intra-arterial injection of thiopental causes severe arterial spasm and an intense burning pain around the injection site. In the case of accidental intra-arterial injection of thiopental the needle should be left in-situ so that an injection of an antispasmodic, such as papaverine or prilocalne hydrochloride may be given. Anticoagulant therapy may also be started to reduce the risk of thrombosis.

Thiopental injection should be used with caution in patients with adrenocortical insufficiency or with raised intracranial pressure.

4.5 Interaction with other medicinal products and other forms of interaction

Thiopental has been shown to interact with sulphafurazole.

It should be noted that thiopental will interact with beta-blockers and calcium antagonists causing a fall in blood pressure.

The sedative properties of antipsychotics and anxiolytics may be potentiated by thiopental.

4.6 Pregnancy and lactation

Thiopental readily crosses the placental barrier and also appears in breast milk. Therefore, breast-feeding should be temporarily suspended or breast milk expressed before the induction of anaesthesia. It has been shown that thiopental can be used without adverse effects during pregnancy although the total dose should not exceed 250mg. However, when considering use of thiopental the clinician should only use the drug when the expected benefits outweigh any potential risks.

4.7 Effects on ability to drive and use machines

Post-operative vertigo, disorientation and sedation may be prolonged and out-patients given thiopental should therefore be advised not to drive or use machinery, especially within the first 24 to 36 hours.

4.8 Undesirable effects

Laryngeal spasm may occur, together with coughing or sneezing, during the induction procedure. For this reason it is not advised to use thiopental alone for peroral endoscopy.

Extravasation causes local tissue necrosis and severe pain. This can be relieved by application of an ice pack and local injection of hydrocortisone. The 5% w/v solution is hypertonic and may cause pain on injection and thrombophlebitis.

Allergic reactions, skin reactions and hypersensitivity have been rarely reported.

Bronchospasm, respiratory depression and myocardial depression or cardiac arrhythmias may occur.

4.9 Overdose

Overdosage produces acute respiratory depression, hypotension, circulatory failure and apnoea. Treatment must be artificial ventilation, lowering of the patient's head and infusion of plasma volume expanders.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Thiopental is a short-acting substituted barbiturate that is more lipid soluble than other groups of barbiturates. The drug reversibly depresses the activity of all excitable tissues. The CNS is particularly sensitive and normally a general anaesthesia can be achieved with thiopental without significant effects on peripheral tissues.

Thiopental injection - electronic Medicines Compendium (eMC) - print friendly

Page 4 of 4

Thiopental acts through the CNS with particular activity in the mesencephalic reticular activating system. The barbiturates exert different effects on synaptic transmission, mostly those dependent on GABA. Autonomic ganglia of the peripheral nervous system are also depressed.

5.2 Pharmacokinetic properties

Following intravenous administration, unconsciousness occurs within 30 seconds and will be continued for 20 to 30 minutes after a single dose. Rapid uptake occurs to most vascular areas of the brain followed by redistribution into other tissues.

Thiopental is strongly bound to plasma protein, which impairs excretion through the kidney. The metabolites are usually inactive and are then excreted. Thiopental, therefore, whilst having a short duration of action, may have a long elimination phase.

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the Summary of Product Characteristics.

6. PHARMACEUTICAL PARTICULARS**6.1 List of excipients**

None

6.2 Incompatibilities

Solutions of thiopental injection have a pH of 10 to 11 and are strongly alkaline in order to maintain stability. Solutions are incompatible with acid, acidic salts and solutions such as pethidine, morphine and promethazine

6.3 Shelf life

48 months.

6.4 Special precautions for storage

Do not store above 25°C. Store reconstituted solution between 2°C to 8°C in an upright position and use within 7 hours. Use once following reconstitution and discard any residue.

6.5 Nature and contents of container

20ml Type III clear glass vials with 20mm bromylbutyl caoutchouc siliconised rubber closures.

Pack size: 25 vials per pack.

6.6 Special precautions for disposal and other handling

Not applicable.

7. MARKETING AUTHORISATION HOLDER

Link Pharmaceuticals Limited, Bishops Weald House, Abdon Way, Horsham, West Sussex RH12 1AH, UK

8. MARKETING AUTHORISATION NUMBER(S)

PL 12406/0014

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

5 April 1999

10. DATE OF REVISION OF THE TEXT

January 2003

11. Legal Category

POM

(b) (4) Manifest report

SEP DT 17-SEP-2010 SHIP# (b) (4) HETER THERMAL (X) RECIPI (b) (4) Sour leg code

(b) (4) (b) (4)

NAME Matt Alavi NAME Att: Wendy Kelly, Deputy Director

COMP Dream Pharma Ltd. COMP Arkansas Department of Correction

ADD1 176 Horn Lane ADD1 Central Administration Office

ADD2 ADD2 6814 Princeton Pike

CITY ACTON, LONDON CITY PINE BLUFF

ST/PR CTRY GB POSTAL W36PJ ST/PR AR CTRY US POSTAL 71602

REF Pharmaceuticals Not Restricted

PKGS (b) (4) WEIGHT (b) (4) K/L K DIM WEIGHT (b) (4)

DESC PHARMACEUTICALS NOT RESTRICTED HS CD 30049099 COM GB CUST VAL EXP DT EXP LIC

(b) (4)

LOCATION MEM NEW INTERNATIONAL AIRBILL ENTRY ENT# 112-8992979-0
FLT/TRK FX001 FTDT 17SEP10 BCH MTR CLC CHKR AB OF
ROUTE FX001 DOC/NC N CO CONT BAG

(b) (4)

NAME MATT ALAVI
COMP DREAM PHARMA LTD.
ADD1 176 HORN LANE
ADD2
CITY ACTON, LONDON
ST/PV CNTRY GB POSTAL W36PJ
REF

(b) (4)

(b) (4)


RECIPIENT PH (870)550-7307
NAME ATT: WENDY KELLY, DEPUTY DIRECTO
COMP ARKANSAS DEPARTMENT OF CORRECTIO
ADD1 CENTRAL ADMINISTRATION OFFICE
ADD2 6814 PRINCETON PIKE
CITY PINE BLUFF
ST/PV AR CNTRY US POSTAL 71602

(b) (4)

(b) (4)

PKGS K/L WEIGHT COM CURR
(b) (4) K (b) (4) GB UKL
DESC: PHARMACEUTICALS NOT RESTRICTED

CARR VAL CUSTOMS VAL EX LIC HDLG UNITS
590.25

**Arkansas Department of Correction**

Wendy Kelley
Deputy Director of Health &
Correctional Programs
P.O. Box 8707
Pine Bluff, Arkansas 71611-8707
Phone: (870) 267-6361
Fax: (870) 267-6363
WENDY.KELLEY@ARKANSAS.GOV

FAX COVER SHEET

SEND TO:

*Jaquelyn
Biddford*

FROM:

Wendy Kelley

FAX #:

901.333.3579

DATE:

9.27.10

TOTAL PGS (INCLUDING COVER):

3

Comments:

PLEASE NOTE: This facsimile and any attachments is the property of the State of Arkansas and may be protected by state and federal laws governing disclosure of private information. It is for the intended recipient only. If an addressing or transmission error has misdirected this facsimile, please notify the sender. If you are not the intended recipient you may not use, disclose, distribute, copy, print or rely on this facsimile. You are notified that the document(s) provided may contain health information that is legally privileged, confidential and protected by law from disclosure. Copying or distributing this information except as required for the direct care and treatment of the designated patient, without the express authorization of the Arkansas Department of Correction, Office of the Administrator of Mental Health or Medical Services, is prohibited.

**Arkansas Department of Correction**

Wendy Kelley
Deputy Director of Health &
Correctional Programs
P.O. Box 8707
Pine Bluff, Arkansas 71611-8707
Phone: (870) 267-6361
Fax: (870) 267-6363
WENDY.L.KELLEY@ARKANSAS.GOV

September 10, 2010

Dream Pharma Ltd.
ATTN: Matt Alavi
176 Horn Lane
Action, London W3 6PJ

SUBJECT: Thiopental Injection Purchase

Dear Mr. Alavi,

The Arkansas Department of Corrections (GDC) uses Thiopental Injection to carry out Capital Punishment in Arkansas. In accordance Arkansas State Law, A.C.A. § 5-4-617, "The sentence of death is to be carried out by intravenous lethal injection of one (1) or more chemicals, as determined in kind and amount in the discretion of the Director of the Department of Correction. The chemical or chemicals injected may include one (1) or more of the following substances: one (1) or more ultra-short-acting barbiturate, one (1) or more chemical paralytic agents, potassium chloride, or any other chemical or chemicals, including but not limited to saline solution." The Director of the Arkansas Department of Correction by Administrative Directive has ordered that sodium pentothal or Thiopental sodium be used for the first chemical.

The Arkansas Department of Correction placed an order earlier this year with a manufacturer in the United States, but has been advised that they have none in stock, nor is any expected this year. In order to carry out the State of Arkansas' constitutional mandates in death penalty cases, we desire to make the following purchase:

Name/Description Quantity	Quantity	Price (ea)	Total
Thiopental Injection, power for reconstitution, thiopental sodium, 500mg vial packs of 25's	(b) (4)	GBP	590.25 GBP

Shipping Location:

**Arkansas Department of Correction
Central Administration Office
ATTN: Wendy Kelley, Deputy Director
6814 Princeton Pike
Pine Bluff, AR 71602-9411
Telephone: 870-550-7307**

United States Drug Enforcement Agency Number (DEA): FA1835199

Our Federal Express account is (b) (4)

I understand the expiration date of the chemical currently available is February 2014. I can be reached by telephone at 001-870-550-7307 or by e-mail: wendy.kelley@arkansas.gov

Sincerely,



**Wendy L. Kelley,
Deputy Director for Health & Correctional Programs
Arkansas Department of Corrections**

From: Kernan, Scott@CDCR [Scott.Kernan@cdcr.ca.gov]
Sent: Thursday, December 09, 2010 2:03 PM
To: Dixon, Ruth P
Cc: McAuliffe, John@CDCR; Rice, Benjamin@CDCR
Subject: FW: Letter to Ms. Dixon

Attachments: Letter to Ms. Dixon0001.pdf

Ms. Dixon,

Thank you for working with Mr. McAuliffe on obtaining FDA approval for the delivery of Sodium thiopental to California. Please find attached a letter detailing our legal procurement of the drug and our urgent interest in obtaining the shipment as soon as possible. Your immediate attention to this matter is greatly appreciated.

Please feel free to contact me should you have any questions. (916) 801-4358.

Sincerely,

Scott Kernan
Undersecretary
California Department of Corrections
And Rehabilitation

From: Gaddi, Kathy@CDCR
Sent: Thursday, December 09, 2010 11:58 AM
To: Kernan, Scott@CDCR
Subject: Letter to Ms. Dixon

Ruth.Dixon@FDA.HHS.gov

Kathy Gaddi
Executive Assistant to Scott Kernan
Undersecretary, Operations
(916) 341-7015

DEPARTMENT OF THE TREASURY
UNITED STATES CUSTOMS SERVICEForm Approved
OMB No. 1515-0069

ENTRY/IMMEDIATE DELIVERY

ABI CERTIFIED

FEDEX TRADE NETWORKS
TRANSPORT & BROKERAGE, INC.

AIR EXPRESS

TEL: (901) 752-3000

19 CFR 142.3, 142.10, 142.22, 142.24

1. ARRIVAL DATE 100610	2. ELECTED ENTRY DATE	3. ENTRY TYPE CODE/NAME 11	4. ENTRY NUMBER 112-9247186-3
5. PORT 2095	6. SINGLE TRANS. BOND	7. BROKER/IMPORTER FILE NUMBER (b) (4)	
	8. CONSIGNEE NUMBER NAME/ADDRESS		9. IMPORTER NUMBER (b) (4)
10. ULTIMATE CONSIGNEE NAME (b) (4)		11. IMPORTER OF RECORD NAME (b) (4)	
12. CARRIER CODE (b) (4)	13. VOYAGE/FLIGHT/TRIP (b) (4)	14. LOCATION OF GOODS CODE(S) NAME(S) (b) (4)	
15. VESSEL CODE/NAME			
16. U.S. PORT OF UNLADING 2095	17. MANIFEST NUMBER	18. G.O. NUMBER	19. TOTAL VALUE (b) (4)
20. DESCRIPTION OF MERCHANDISE PHARMACEUTICALS NOT RESTRICTED			
21. I7BLAWB CODE M H	22. I7BLAWB NO. TOTAL (b) (4)	23. MANIFEST QUANTITY (b) (4)	24. H.S. NUMBER 3004.90.9190
			25. COUNTRY OF ORIGIN GB
			26. MANUFACTURER ID. GBDREPHA176LON

27. CERTIFICATION

I hereby make application for entry/immmediate delivery. I certify that the above information is accurate, the bond is sufficient, valid, and current, and that all requirements of 19 CFR Part 142 have been met.

SIGNATURE OF APPLICANT

(b) (6)

PHONE NO.

(b) (4)

DATE

10/07/10

28. BROKER OR OTHER GOVT. AGENCY USE

28. CUSTOMS USE ONLY

☐ OTHER AGENCY ACTION REQUIRED, NAMELY:☐ CUSTOMS EXAMINATION REQUIRED.☐ ENTRY REJECTED, BECAUSE:DELIVERY
AUTHORIZED:

SIGNATURE

DATE

Dream Pharma Ltd.

176 Horn Lane, Acton, London, W3 6PJ
Tel: 020 8992 7000 Fax: 020 8992 7001
E-Mail: info@dreampharma.com

Invoice Details

Number: 2682INV

Date: 06-10-2010

Address:

(b) (4)

Delivery Address:

(b) (4)

VAT no:

Purchase Order:

Currency: GBP - Pounds sterling

Heading: PHARMACEUTICALS NOT RESTRICTED

Order Details

Name/Description	Quantity	Price	Total
Thiopental Injection , powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's Batch No: AW6022 EXP: 05/14	(b) (4)	(b) (4)	(b) (4)
Previous balance		(b) (4)	

Statement Details

Goods Total: (b) (4)	Subtotal: (b) (4)
Discount (%): (b) (4)	VAT (World Zero): (b) (4)
Deliver: (b) (4)	Previous Balance: (b) (4)
Insurance: (b) (4)	Total: (b) (4) GBP - Pounds sterling
	Payment Method: Prepayment Thank You

Shipping Details

Packing: one box	Gross Weight (Kg): (b) (4)
Tariff: 30049099	Net Weight (Kg): (b) (4)
Declarations: We certify that this invoice is true and correct.	Carrier: (b) (4)
	Matt Alavi, for Dream Pharma Ltd.

DREAM PHARMA LTD
176 Horn Lane
Acton, London W3 6PJ
Tel: 020-8992-7000
Fax: 020-8992-7001

Damage, shortage or leakage must be notified in writing to ourselves within 3 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale. E&OE

Company Registration Number: 4637884 VAT No. GB805-5541-41

Director: M. Alavi

ENTRY NUMBER: 112 9247186 3

AWB/BL NBR : (b) (4)

INVOICE #
LINE CONSOL. WORKSHEET

PAGE: 1

10/07/2010

05:38 PM

ITEMS MARKED 1 C/O- GB
TARIFF # 3004.90.9190

QTY 1: KG
(b) (4)

LINE VALUE- GBP

(b) (4)

**

**

*** END OF REPORT ***

ENTRY NUMBER: 112 9247186 3

AWB/BL NBR : (b) (4) INVOICE #

SHIPPER : DREAM PHARMA LTD

PAGE: 1

10/07/2010

05:38 PM

ITEM MARKED REFERENCE

INVOICE LINE#	ITEM MARK	TARIFF NUMBER	COUNTRY OF ORIG.	RATE OF DUTY
------------------	--------------	------------------	---------------------	--------------

VALUE-GBP

1	(b) (4)	3004.90.9190	GB	
---	---------	--------------	----	--

Q:

(b) (4)

*** END OF REPORT ***

(b) (4) Manifest report

SHP DT 08-OCT-2010 SHPR (b) (4) PETER THERMAL RECP (b) (4) Packing code
AB (b) (4) PF (b) (4) RECIPIENT (b) (4) CON (b) (4)
NAME Mail Alavi
COMP Dream Pharma Ltd.
ADDR 175 Horn Lane
ADDR
CITY ACTON, LONDON
ST/PT CTRY GB POSTAL W38PJ
CITY
ST/PT
REF Pharmaceuticals Not Restricted
PKGS (b) (4) WEIGHT (b) (4) K/L K DIM WEIGHT (b) (4) SZ. K
DESC PHARMACEUTICALS NOT RESTRICTED AS CO 30049000 CTRY GB CUST VAL 0 EST DTG SHP DTG

(b) (4)

LOCATION MEM NEW INTERNATIONAL AIRBILL ENTRY ENT# 112-9247186-3

(b) (4)

NAME MATT ALAVI
COMP DREAM PHARMA LTD.
ADD1 176 HORN LANE
ADD2
CITY ACTON, LONDON
ST/PV CENTRY GB POSTAL W36PJ

NAME
COMP
ADD1
ADD2
CITY
ST/PV

(b) (4)

(b) (4)

PKGS	K/L	WEIGHT	COM	CURR	CARR VAL	CUSTOMS VAL	EX	LIC	HDLG	UNITS
(b) (4)	K	(b) (4)	GB	UKL		(b) (4)				

DESC: PHARMACEUTICALS NOT RESTRICTED

From: McAuliffe, John@CDCR [John.McAuliffe@cdcr.ca.gov]
Sent: Monday, December 20, 2010 12:44 PM
To: Dixon, Ruth P
Cc: Kernan, Scott@CDCR
Subject: FW: Letter to Ms. Dixon

Attachments: Letter to Ms. Dixon0001.pdf

Ms. Dixon

Could you please update us on the approval of delivery of the Sodium Thiopental to the California Department of Corrections and Rehabilitation. Thank you in advance.

John McAuliffe

From: McAuliffe, John@CDCR
Sent: Thursday, December 09, 2010 12:10 PM
To: McCleave, Kelly@CDCR
Subject: FW: Letter to Ms. Dixon

FYI

From: Kernan, Scott@CDCR
Sent: Thursday, December 09, 2010 12:03 PM
To: Ruth.Dixon@FDA.HHS.gov
Cc: McAuliffe, John@CDCR; Rice, Benjamin@CDCR
Subject: FW: Letter to Ms. Dixon

Ms. Dixon,

Thank you for working with Mr. McAuliffe on obtaining FDA approval for the delivery of Sodium thiopental to California. Please find attached a letter detailing our legal procurement of the drug and our urgent interest in obtaining the shipment as soon as possible. Your immediate attention to this matter is greatly appreciated.

Please feel free to contact me should you have any questions. (916) 801-4358.

Sincerely,

Scott Kernan
Undersecretary
California Department of Corrections
And Rehabilitation

From: Gaddi, Kathy@CDCR
Sent: Thursday, December 09, 2010 11:58 AM
To: Kernan, Scott@CDCR
Subject: Letter to Ms. Dixon

Ruth.Dixon@FDA.HHS.gov

Kathy Gaddi
Executive Assistant to Scott Kernan

Undersecretary, Operations
(916) 341-7015

United States Food and Drug Administration

New Orleans District Office

Notice of FDA Action

Entry Number: 112-9673446-4

Notice Number: 2

January 6, 2011

Consignee:

Kirkland Correctional Institutio
4344 Broad River Rd
Columbia, SC 29210-4010

>

Port of Entry: 2095, FedEx - Memphis, Memphis, TN

Carrier: (b) (4)

Date Received: November 5, 2010

Arrival Date: November 5, 2010

Filer of Record: FEDEX Trade Networks Transport and Brokerage, Memphis, TN 38125

Importer of Record: (b) (4)

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
* 001/001	688760418804/THIOPENTAL SODIUM	(b) (4)	Released 01-06-2011

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 112-9673446-4. Any status changes are reflected in the Line summary and line detail sections.

CORRESPONDENCE

Line ACS/FDA	Product Description
001/001	688760418804/THIOPENTAL SODIUM

Comments: FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity or any other characteristics

Denise D. Duncan, Compliance Officer
(Region/District)

(901) 333-3520
(901) 333-3579 (FAX)
DENISE.DUNCAN@FDA.HHS.GOV

Notice of FDA Action
Entry Number: 112-9673446-4

Notice Number: 2
Page: 2

U.S. Food and Drug Administration
959 Ridgeway Loop Road, Suite 100
Memphis, TN 38120-4042

LINES RELEASED

Line ACS/FDA	Product Description
001/001	688760418804/THIOPENTAL SODIUM
<hr/>	
Denise D. Duncan, Compliance Officer (Region/District) U.S. Food and Drug Administration 959 Ridgeway Loop Road, Suite 100 Memphis, TN 38120-4042	(901) 333-3520 (901) 333-3579 (FAX) DENISE.DUNCAN@FDA.HHS.GOV

These products are released. This notice does not constitute assurance that the product released complies with all provisions of the Food, Drug, and Cosmetic Act, or other related Acts, and does not preclude action should the product later be found violative.

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: DDD

#2 Martin Luther King, Jr. Drive
East Tower, Room 754
Atlanta, GA 30334
Fax (404) 657-4399
Voice (404) 656-5999

**Georgia Department
of Corrections
Purchasing**

Fax

Faxed
8/10/10
JR 2:28 P.M.

To: B. JEFFERSON

From: C. SMITH

Fax: 901.333.3579

Pages: 3 (INCLUDING COVER PAGE)

Phone:

Date:

TRANSLING # 688760417429

Re: ENTRY # 112-7818637-8 CC:

☐ Urgent ☐ For Review ☐ Please Comment ☐ Please Reply ☐ Please Recycle

**GEORGIA DEPARTMENT OF CORRECTIONS**

COMMISSIONER'S OFFICE
SUITE 866, EAST TOWER
2 MARTIN LUTHER KING, JR. DRIVE, S.E.
ATLANTA, GEORGIA 30334-4900
404/656-4644
FAX 404/651-6818

Sonny Perdue
Governor

Brian Owens
Commissioner

August 4, 2010

FEDEX
ATTN: Customer Relations
3875 Airways, Module H3 Department 4634
Memphis, TN 38116

SUBJECT: Thiopental Injection Purchase

To whom it may Concern:

The Georgia Department of Corrections (GDC) uses Thiopental Injection in its Death Sentence cases. In accordance with Official Code of Georgia, § 17-10-3, Article 2 in capital punishment cases: "All persons who have been convicted of a capital offense and have had imposed upon them a sentence of death shall suffer such punishment by lethal injection."

The GDC has been unable to locate this drug in the United States and because there is a need for the drug to carry out the State of Georgia's constitutional requirement in death sentence cases we have purchased, from Dream Pharma LTD., 176 Horn Lane, Action London, the supplies listed below:

Name/Description	Quantity	Price (ea)	Total
Thiopental Injection, power for reconstitution, thiopental sodium, 500mg vial packs of 25's	(b) (4)		91.88 GBP


Shipping Location:

(b) (4)

SUBJECT: Thiopental Injection Purchase
Georgia Department of Corrections

Mr. Charles H. Smith, Jr., Director of Procurement will be the point of contact for this purchase.
He can be reached by telephone 404-656-6442 or by e-mail: smithc12@dcor.state.ga.us.

Sincerely,



Derrick D. Schofield,
Assistant Commissioner, Chief of Staff
Georgia Department of Corrections

DEPARTMENT OF THE TREASURY
UNITED STATES CUSTOMS SERVICEForm Approved
OMB No. 1515-0069

ENTRY/IMMEDIATE DELIVERY

ABI CERTIFIED

FEDEX TRADE NETWORKS
TRANSPORT & BROKERAGE, INC.

AIR EXPRESS

TEL: (901) 752-3000

19 CFR 142.3, 142.16, 142.22, 142.24

1. ARRIVAL DATE 110510	2. ELECTED ENTRY DATE	3. ENTRY TYPE CODE/NAME 11	4. ENTRY NUMBER 112-9673446-4
5. PORT 2095	6. SINGLE TRANS. BOND	7. BROKER/IMPORTER FILE NUMBER (b) (4)	
	8. CONSIGNEE NUMBER NAME/ADDRESS	9. IMPORTER NUMBER (b) (4)	
10. ULTIMATE CONSIGNEE NAME KIRKLAND CORRECTIONAL IN 4344 BROAD RIVER RD COLUMBIA SC		11. IMPORTER OF RECORD NAME (b) (4)	
12. CARRIER CODE (b) (4)	13. VOYAGE/FLIGHT/TRIP (b) (4)	14. LOCATION OF GOODS-CODE(S)/NAME(S) (b) (4)	
15. VESSEL CODE/NAME			
16. U.S. PORT OF UNLADING 2095	17. MANIFEST NUMBER	18. G.O. NUMBER	19. TOTAL VALUE 1034
20. DESCRIPTION OF MERCHANDISE PHARMACEUTICALS NOT RESTRICTED			
21. IT/BL/AWB CODE M H	22. IT/BL/AWB NO. TOTAL (b) (4)	23. MANIFEST QUANTITY (b) (4)	24. H.S. NUMBER 3004.90.9135
			25. COUNTRY OF ORIGIN GB
			26. MANUFACTURER ID. GBDREPHA176LON

27. CERTIFICATION

I hereby make application for entry/immediate delivery. I certify that the above information is accurate, the bond is sufficient, valid, and current, and that all requirements of 19 CFR Part 142 have been met.

SIGNATURE OF APPLICANT

(b) (6)

PHONE NO.

(b) (4)

DATE

11/05/10

29. BROKER OR OTHER GOVT. AGENCY USE

28. CUSTOMS USE ONLY

☐ OTHER AGENCY ACTION REQUIRED, NAMELY:☐ CUSTOMS EXAMINATION REQUIRED.☐ ENTRY REJECTED, BECAUSE:DELIVERY
AUTHORIZED:

SIGNATURE

DATE

Dream Pharma Ltd.

176 Horn Lane, Acton, London, W3 6PJ
Tel: 020 8992 7000 Fax: 020 8992 7001
E-Mail: info@dreampharma.com

Invoice Details

Number: 2716INV

Date: 05-11-2010

Address:

South Carolina Department of Corrections
Kirkland Correctional Institution- Pharmacy
4344 Broad River Road
Columbia, South Carolina 29210
United States

Tel: 803 - 896-1995

VAT no:

Purchase Order:

Delivery Address:

South Carolina Department of Corrections
Att: John Solomon and Rose Mayer
Kirkland Correctional Institution- Pharmacy
4344 Broad River Road
Columbia, South Carolina 29210
United States
803 - 896-1995

Currency: USD - US Dollar

Heading: PHARMACEUTICALS NOT RESTRICTED

Order Details

Name/Description	Quantity	Price	Total
Thiopental Injection , powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's Batch No: AW6022 EXP: 05/14	(b) (4)		1033.5

Statement Details

Goods Total: 1033.50	Subtotal: 1471.00
Discount (%): 0	VAT (World Zero): 0.00
Delivery: 437.5	Previous Balance: 0
Insurance: 0	Total: 1471.00 USD - US Dollar
Payment Method: Prepayment Thank You	

Shipping Details

Packing: (b) (4)	Gross Weight (Kg): (b) (4) Net Weight (Kg): (b) (4)
Tariff: 30049099	Carrier: (b) (4)
Declarations: We certify that this invoice is true and correct.	Matt Alavi, for Dream Pharma Ltd. 176 Horn Lane Acton, London W3 6PJ Tel: 020-8992-7000 Fax: 020-8992-7001

Damage, shortage or leakage must be notified in writing to ourselves within 3 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale. E&OE

Company Registration Number: 4637884 VAT No. GB805-5541-41
Director: M. Alavi

Page 1 of 1

ENTRY NUMBER: 112 9673446 4

AWB/BL NBR : (b) (4)

INVOICE #
LINE CONSOL. WORKSHEET

PAGE: 1
11/05/2010
08:19 PM

ITEMS MARKED 1 C/O- GB
TARIFF # 3004.90.9135
QTY 1: KG
(b) (4)

LINE VALUE- USD

1,033.50

**

** 1,033.50

**** 1,033.50

*** END OF REPORT ***

ENTRY NUMBER: 112 9673446 4

AWB/BL NBR : (b) (4)

INVOICE #

SHIPPER : DREAM PHARMA LTD

ITEM MARKED REFERENCE

PAGE: 1

11/05/2010

08:19 PM

INVOICE LINE#	ITEM MARK	TARIFF NUMBER	COUNTRY OF ORIG.	RATE OF DUTY
------------------	--------------	------------------	---------------------	--------------

VALUE-USD

1

(b) (4)

3004.90.9135 GB

Q:

(b) (4) KG
1,033.50

*** END OF REPORT ***

FDA_08.18.11_000081

(b) (4) Manifest report

SHIP DT 05-NOV-2010 SHIPP (b) (4) METER INTERNAL ☒ RECEIPT
AS (b) (4) PE 0208-992-7000 RECEIPT PR 803 896 1995 ETR
NAME Matt Alavi DOA John Solomon and Rose Mayer
COMP Dream Pharma Ltd. COMP South Carolina Department of Correc
ADDR1 176 Horn Lane ADDR Kirkland Correctional Institution-
ADDR2 ADDR 4344 Broad River Road
CITY ACTON, LONDON CITY COLUMBIA
ST/PR CTRY GB FONTAL W36PJ ST/PR SC CTRY US POSTAL 29210
REF Pharmaceuticals Not Restricted
PKGS (b) (4) WEIGHT (b) (4) N/L K DIM WEIGHT (b) (4) N/L (b) (4)
DESC PHARMACEUTICALS NOT RESTRICTED (b) (4) ECH GB CUS VAL EXP DT EXP LIC

(b) (4)

LOCATION MEM NEW INTERNATIONAL AIRBILL ENTRY ENT# 112-9673446-4

(b) (4)

(b) (4)

NAME MATT ALAVI
COMP DREAM PHARMA LTD.
ADD1 176 HORN LANE
ADD2
CITY ACTON, LONDON
ST/PV CNTRY GB POSTAL W36PJ
REF

RECIPIENT PH (803)896-1995

NAME JOHN SOLOMON AND ROSE MAYER
COMP SOUTH CAROLINA DEPARTMENT OF COR
ADD1 KIRKLAND CORRECTIONAL INSTITUTIO
ADD2 4344 BROAD RIVER ROAD
CITY COLUMBIA
ST/PV SC CNTRY US POSTAL 29210

(b) (4)

PKGS	K/L	WEIGHT	COM	CARR	VAL	CUSTOMS	VAL	EX	LIC	HDLG	UNITS
(b) (4)	K	(b) (4)	GB	USD			1471.00				
DESC: PHARMACEUTICALS NOT RESTRICTED											

United States Food and Drug Administration

New Orleans District Office

Notice of FDA Action

Entry Number: 112-9673446-4

Notice Number: 1

November 8, 2010

Consignee:

Kirkland Correctional Institutio
4344 Broad River Rd
Columbia, SC 29210-4010

> <

Port of Entry: 2095, FedEx - Memphis, Memphis, TN
Carrier: (b) (4);
Date Received: November 5, 2010
Arrival Date: November 5, 2010
Filer of Record: FEDEX Trade Networks Transport and Brokerage, Memphis, TN 38125
Importer of Record: (b) (4)

HOLD DESIGNATED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
001/001	688760418804/THIOPENTAL SODIUM	(b) (4)	Pending FDA Review 11- 05-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

FDA will not request redelivery for examination or sampling, if the products not released by FDA are moved, following USCS conditional release to a location within the local metropolitan area or to a location approved by the FDA office at the number below.

All products in this entry not listed above may proceed without FDA examination. This notice does not constitute assurance the products involved comply with provisions of the Food, Drug, and Cosmetic Act or other related acts, and does not preclude action should the products later be found violative.

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: MJS

DEPARTMENT OF HOMELAND SECURITY
U.S. Customs and Border Protection

Form Approved
OMB No. 1515-0024
Exp. 01-31-2012

ENTRY/IMMEDIATE DELIVERY

ACB IMPORT SERVICES, INC
DBA ARIZONA CUSTOMS BROKERS
P.O. BOX 20082
PHOENIX, AZ 85036

000 BOX #

19 CFR 142.3, 142.16, 142.22, 142.24

ABI CERTIFIED

1. ARRIVAL DATE 102610	2. ELECTED ENTRY DATE	3. ENTRY TYPE CODE/NAME 11 INFORMAL -	4. ENTRY NUMBER 574-0251126-5
5. PORT 2605	6. SINGLE TRANS. BOND (b) (4)	7. BROKER/IMPORTER FILE NUMBER 001267045	
	8. CONSIGNEE NUMBER 86-600479107		9. IMPORTER NUMBER 86-600479106
10. ULTIMATE CONSIGNEE NAME ARIZONA STATE PRISON COMPLEX 1305 BUTTE AVE FLORENCE, AZ 85232		11. IMPORTER OF RECORD NAME ARIZONA DEPARTMENT OF CORRECTIONS 1601 W. JEFFERSON ST PHOENIX, AZ 85007-3002	
12. CARRIER CODE (b) (4)	13. VOYAGE/FLIGHT/TRIP (b) (4)	14. LOCATION OF GOODS CODE(S)/NAME(S) (b) (4) 2(b) (4) PHOENIX, AZ 85034	
15. VESSEL CODE/NAME			
16. U.S. PORT OF UNLADING 2605	17. MANIFEST NUMBER	18. G.S. NUMBER	19. TOTAL VALUE 1246
20. DESCRIPTION OF MERCHANDISE MEDICAL EQUIPMENT			
21. IT/BL/AWS NO. COOL	22. IT/BL/AWS NO. (b) (4)	23. MANIFEST QUANTITY (b) (4)	24. H.S. NUMBER 3004909130
		25. COUNTRY OF ORIGIN GB	26. MANUFACTURER NO. GBDREPHA176LON

27. CERTIFICATION

I hereby make application for entry/immediate delivery. I certify that the above information is accurate, the bond is sufficient, valid, and current, and that all requirements of 19 CFR Part 142 have been met.

SIGNATURE OF APPLICANT

X ATTY-IN-FACT/ACB

PHONE NO. (b) (6)

Fax# (b) (6) 10/25/2010

28. BROKER OR OTHER GOVT. AGENCY USE

28. CBP USE ONLY

☐ OTHER AGENCY ACTION REQUIRED, NAMELY:

☐ CBP EXAMINATION REQUIRED.

☐ ENTRY REJECTED, BECAUSE:

DELIVERY
AUTHORIZED:

SIGNATURE

DATE

Exam Site: (b) (4)

Paperwork Reduction Act Statement: An agency may not conduct or sponsor an information collection and a person is not required to respond to this information unless it displays a current valid OMB control number and an expiration date. The control number for this collection is 1515-0024. The estimated average time to complete this application is 15 minutes. If you have any comments regarding the burden estimate you can write to U.S. Customs and Border Protection, Office of Regulations and Rulings, 799 9th Street, NW, Washington DC 20229.



JANICE K. BREWER
GOVERNOR

Arizona Department of Corrections

1001 WEST JEFFERSON
PHOENIX, ARIZONA 85007
(602) 542-6487
www.azcorrections.gov



CHARLES L. RYAN
DIRECTOR

September 24, 2010

David Thomas, DCM
FDA Investigations
Food and Drug Administration
Division of Import Operations and Policy
4605 East Elwood Street, Suite 402
Phoenix, Arizona 85040-1948

Re: Execution by Lethal Injection of Arizona Inmate
Jeffrey Timothy Landrigan #082157

Dear Mr. Thomas:

The purpose of this correspondence is to advise your agency of our intent to receive certain pharmaceutical products from Dream Pharma, Ltd. of London, England. We have placed the order with this company for the purpose of securing the necessary drugs for carrying out an execution warrant issued by the Arizona Supreme Court in the matter of State v. Jeffrey Timothy Landrigan, CR-90-0323 AP.

In order to proceed with the execution we must have the products ordered through Dream Pharma. Our DEA Registration number is: FA2203571 and it expires June 30, 2013. The execution is set by the court for October 26, 2010, and our agency is mandated to advise the court that it possesses the necessary chemicals for the lethal injection protocol as approved, no later than October 1, 2010.

Any steps your agency can take in attending to this shipment expeditiously would be of great assistance to our agency in its effort to abide by the court-ordered dates set by the court. Should your agency have any questions, do not hesitate to contact my office directly at (602) 542-5225 or after normal business hours through our command center at (602) 542-1212.

Thank you in advance for your professional assistance with the processing of this shipment.

Sincerely,

Charles L. Ryan
Director

cc: Charles Flanagan, Deputy Director
Robert Patton, Division Director, Offender Operations
Carson McWilliams, Warden, ASPC Florence

Dream Pharma Ltd.

176 Horn Lane, Acton, London, W3 8PJ
Tel: 020 8992 7000 Fax: 020 8992 7001
E-Mail: info@dreampharma.com

Invoice Details

Number: 2701NV

Date: 22-10-2010

Address:

Arizona State Prison Complex - Florence
Attention: Carson McWilliams, Warden
1305 Butte Avenue
Post Office Box 629
Florence, Arizona
85232
Tel: 602-364-3791

Delivery Address:

Arizona State Prison Complex - Florence
Attention: Carson McWilliams, Warden
1305 Butte Avenue
Post Office Box 529
Florence, Arizona
85232
602-364-3791

VAT no:

Purchase Order:

Currency: GBP - Pounds sterling

Heading: PHARMACEUTICALS NOT RESTRICTED

"This is not for use by the general public"

Order Details


Name/Description	Quantity	Price	Total
Thiopental Injection , powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's Batch No: AW8022 EXP: 05/14 3004.90.9130/	(b) (4)	(b) (4)	787

Statement Details

Goods Total: 787.00	Subtotal: 787.00
Discount (%): 0	VAT (World Zero): 0.00
Delivery: 0	Previous Balance: 0
Insurance: 0	Total: <u>787.00</u> GBP - Pounds sterling
	Payment Method: Prepayment Thank You

1-58270
1245

Shipping Details

Packing: (b) (4) Tariff: 30049099	Gross Weight (Kg): (b) (4) Net Weight (Kg): (b) (4) Carrier: (b) (4)
Declarations: We certify that this invoice is true and correct.	Matt Alavi, for Dream Pharma Ltd. 

Damage, shortage or leakage must be notified in writing to ourselves within 3 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale. F&OE

Company Registration Number: 4837884 VAT No. GB805-5641-41
Director: M. Alayi

Page 1 of 1

Dream Pharma Ltd.

176 Horn Lane, Acton, London, W3 6PJ
Tel: 020 8992 7000 Fax: 020 8992 7001
E-Mail: info@dreampharma.com

Invoice Details

Number: 2702INV

Date: 22-10-2010

Address:

Arizona State Prison Complex - Florence
Attention: Carson McWilliams, Warden
1305 Butte Avenue
Post Office Box 829
Florence, Arizona
85232
Tel: 602-384-3791

Delivery Address:

Arizona State Prison Complex - Florence
Attention: Carson McWilliams, Warden
1305 Butte Avenue
Post Office Box 829
Florence, Arizona
85232
602-384-3791

VAT no:

Purchase Order:

Currency: GBP - Pounds sterling

Heading: PHARMACEUTICALS NOT RESTRICTED


Order Details

Name/Description	Quantity	Price	Total
Shipping charges for Invoice number 2701Inv	(b) (4)	(b) (4)	250

Statement Details

Goods Total: 250.00	Subtotal: 250.00
Discount (%): 0	VAT (World Zero): 0.00
Delivery: 0	Previous Balance: 0
Insurance: 0	Total: 250.00 GBP - Pounds sterling
	Payment Method: Prepayment Thank You

Shipping Details

Packing:	Gross Weight (Kg):
Tariff: 30049089	Net Weight (Kg): (b) (4)
Declarations:	Carrier: (b) (4)
We certify that this invoice is true and correct.	Matt Alavi, for Dream Pharma Ltd.
	 DREAM PHARMA LTD 176 Horn Lane Acton, London W3 6PJ Tel: 020-8992-7000 Fax: 020-8992-7001

Damage, shortage or leakage must be notified in writing to ourselves within 3 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale. E&OE

Company Registration Number: 4637884 VAT No. GB805-6641-41
Director: M. Alavi

Page 1 of 1

DEA REGISTRATION NUMBER FA253871		THIS REGISTRATION EXPIRES 06-30-2013		FEE PAID Exempt	
SCHEDULES 2,IN,1 3N,4,5		BUSINESS ACTIVITY HOSPITAL/CLINIC		DATE ISSUED 06-25-2010	
ARIZONA STATE PRISON - FLORENCE, CARSON A., WARDEN 1386 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85233 0000					

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

This registration is only for use at Federal or State institutions.

Sections 304 and 1006 (21 U.S.C. 824 and 866) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IS NOT VALID AFTER THE EXPIRATION DATE.

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE UNITED STATES DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WASHINGTON, D.C. 20537					
DEA REGISTRATION NUMBER FA253871		THIS REGISTRATION EXPIRES 06-30-2013		FEE PAID Exempt	
SCHEDULES 2,IN,1 3N,4,5		BUSINESS ACTIVITY HOSPITAL/CLINIC		DATE ISSUED 06-25-2010	
ARIZONA STATE PRISON - FLORENCE, CARSON A., WARDEN 1386 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85233 0000					

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.

Sections 304 and 1006 (21 U.S.C. 824 and 866) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

DEA REGISTRATION NUMBER FA2203671	THIS REGISTRATION EXPIRES 06-30-2013	FEE PAID FEE EXEMPT
SCHEDULES 3, 3N, 4, 5	BUSINESS ACTIVITY HOSPITAL/CLINIC	ISSUE DATE 08-25-2010
ARIZONA STATE PRISON - FLORENCE, CARSON WARDEN 1305 BUTTE AVE. P.O. BOX 629 FLORENCE, ARIZONA 85203		

<p align="center">CONTROLLED SUBSTANCE/REGULATED CHEMICAL REGISTRATION CERTIFICATE</p> <p align="center">UNITED STATES DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WASHINGTON D.C. 20537</p> <p>This registration is only for use at Federal or State Institutions.</p> <p>Sections 904 and 1008 (21 USC 824 and 858) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.</p> <p>THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.</p>
--

<p align="center">REPORT</p>	<p align="center">REQUESTING MODIFICATIONS TO YOUR REGISTRATION CERTIFICATE</p> <p>To request a change to your registered name, address, the drug schedule or the drug codes you handle, please</p> <p align="center">* Visit our web site at www.deadiversion.usdoj.gov - or</p>
-------------------------------------	--

ARIZONA STATE PRISON - FLORENCE, CARSON
WARDEN
1306 BUTTE AVE.
P.O. BOX 829
FLORENCE, AZ 85232-0000-000

|||||

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID	CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE UNITED STATES DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WASHINGTON D.C. 20537 This registration is only for use at Federal or State Institutions. Sections 304 and 1008 (21 USC 824 and 888) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance. THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.
FA2203671	08-30-2013	FEE EXEMPT	
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE	
2,3N,4,5	HOSPITAL/CLINIC	08-25-2010	
ARIZONA STATE PRISON - FLORENCE, CARSON WARDEN 1306 BUTTE AVE. P.O. BOX 829 FLORENCE, AZ 85232-0000			

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE UNITED STATES DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WASHINGTON D.C. 20537			
DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID	This registration is only for use at Federal or State Institutions. Sections 304 and 1008 (21 USC 824 and 888) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.
FA2203671	08-30-2013	FEE EXEMPT	
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE	
2,3N,4,5	HOSPITAL/CLINIC	08-25-2010	
ARIZONA STATE PRISON - FLORENCE, CARSON WARDEN 1306 BUTTE AVE. P.O. BOX 829 FLORENCE, AZ 85232-0000			
THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.			

Form DEA-225 (4/07)

From: John Solomon [Solomon.John@doc.state.sc.us]

Sent: Wednesday, January 05, 2011 9:21 AM

To: Halpenny, Susan M

Subject: Na Thiopental

Good morning Susan,

The drugs have not been released as of 10:15 this morning. Have you heard anything this morning that is encouraging about this matter?

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

From: Halpenny, Susan M
Sent: Wednesday, January 05, 2011 10:20 AM
To: 'John Solomon'
Subject: RE: Na Thiopental
Good day,

Our Director of Imports, Domenic Veneziano, advised me yesterday that we may not receive the information he was preparing until today. I will let contact you once I have received this information and released the shipments.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

From: John Solomon [mailto:Solomon.John@doc.state.sc.us]
Sent: Wednesday, January 05, 2011 9:21 AM
To: Halpenny, Susan M
Subject: Na Thiopental

Good morning Susan,

The drugs have not been released as of 10:15 this morning. Have you heard anything this morning that is encouraging about this matter?

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

ABI Certified

19 CFR 142.3, 142.16, 142.22, 142.24

FDA 08.18.11 000094

09-28-10 09:00 FROM-ADC Directors Office 602-364-0601

T-087 P0003/0005 F-565

Dream Pharma Ltd.

175 Horn Lane, Acton, London, W3 6PJ
 Tel: 020 8992 7000 Fax: 020 8992 7001
 E-Mail: info@dreampharma.com

Invoice Details

Number: 2579INV

Date: 28-09-2010

Address:

Arizona State Prison Complex - Florence
 Attention: Carson McWilliams, Warden
 1905 Suite Avenue
 Post Office Box 629
 Florence, Arizona
 85232
 Tel: 602-364-3791

Delivery Address:

Arizona State Prison Complex - Florence
 Attention: Carson McWilliams, Warden
 1905 Suite Avenue
 Post Office Box 629
 Florence, Arizona
 85232
 602-364-3791

VAT no:

Purchase Order:

Currency: GBP - Pounds sterling

Heading: PHARMACEUTICALS NOT RESTRICTED

1 - 3004.94.9130 / FM
 2 - 3104.20.0000 / 6.57
 3 - 2733.37.4100 / R

Order Details

Name/Description	Quantity	Price	Total
Thiopental injection, powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's Batch No: AWA022 EXP: 05/14	(b) (4)	(b) (4)	1180.6
POTASSIUM CHLORIDE 1.50M 10ML INJ. PACKS OF 10 Batch No: 002067 EXP: 01/13	(b) (4)	(b) (4)	279.9
Pencuronium injection, pencuronium bromide 2 mg/mL, 3-mL amp packs of 10's Batch No: 949064 EXP: 11/11	(b) (4)	(b) (4)	2842.85
Special delivery charges	1	180	180

Statement Details

Goods Total: 4253.26	Subtotal: 4253.26
Discount (%): 0	VAT (World Zero): 0.00
Delivery: 275	Previous Balance: 0
Insurance: 0	Total: 4528.26 GBP - Pounds sterling
	Payment Method: Prepayment Thank You

Shipping Details

Packing: (b) (4)	Gross Weight (Kg): (b) (4)
Term: 30049099	Net Weight (Kg): (b) (4)
Declarations: We certify that this invoice is true and correct.	Carrier: (b) (4)
	Matt Alavi for Dream Pharma Ltd

Damage, shortage or leakage must be notified in writing to ourselves within 5 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale, F&OE

Company Registration Number: 4837884 VAT No. GB005-8541-41
 Director: M. Alavi

Page 1 of 1

OMB No. 1551-0003 Exp. 12-31-2010

19 CFR 10.60, 10.61, 123.41, 123.42

TRANSPORTATION ENTRY AND MANIFEST OF GOODS SUBJECT TO CBP INSPECTION AND PERMIT U.S. Customs and Border Protection

Entry No. 200610185

Class of Entry I.T. 61

(I.T.) (T.E.) (WD.1E) (Drawback, etc.)

Entry No. _____

Port _____

Date _____

PORT FIRST U.S. PORT
CODE NO. 2095 OF UNLADING MEMPHIS, TN

PORT OF MEMPHIS, TN

DATE 29SEP10

Entered or imported by (b) (4) Importer/IRS # (b) (4) to be shipped

in bond via (b) (4) (Vessel or carrier) (Car number and Initial) (Pier or station) consigned to

CBP Port Director PHOENIX, AZ 2605

Final foreign destination

Consignee CARSON MCWILLIAMS (WARDEN), ARIZONA STATE PRISON COMPLEX (FLOR, FLORENCE, US
(At CBP port of exit or destination)

Foreign port of lading B/L No. (b) (4) Date of sailing

Imported on the (b) (4) (Name of vessel or carrier and motive power) Flag USA on (b) (4) via STN
(Date imported) (Last foreign port)Exported from UNITED KINGDOM on 28SEP10 Goods now at (b) (4)
(Country) (Date) (Name of warehouse, station, pier, etc.)

Marks and Numbers of Packages	Description and Quantity of Merchandise Number and Kind of Packages (Describe fully as per shipping papers)	Gross Weight in Pounds	Value (Dollars only)	Rate	Duty
(b) (4)	872136481249 PHARMACEUTICALS NOT RESTRICTED THIOPENTAL INJECTION POWDER FOR RECONSTITUTION THIOPENTAL SODIUM 500- MG VIAL PACKS OF 25'S BATCH NO AW6022 EXP 051.4 POTASSIU *** BROKER INFORMATION *** ARIZONA CUSTOMS PHOENIX ARIZ, AZ, US, 85040 CONTACT: 6022730912	ESTIMATED NOT (b) (4)	VERIFIED 6822.00 USD		

G.O. No. ☐ Check if withdrawn for Vessel supplies (19 U.S.C. 1309)

CERTIFICATE OF LADING FOR TRANSPORTATION IN BOND AND/OR LADING FOR EXPORTATION FOR PHOENIX, AZ 2605 (Port)

WITH THE EXCEPTIONS NOTED ABOVE, THE
WITHIN-DESCRIBED GOODS WERE:

Delivered to the Carrier
named above, for delivery to
the CBP Port Director at
destination sealed with CBP
seals Nos. WAIVED
or the packages (were) (were
not) labeled, or corded
and sealed.

Laden on the--

(Vessel, vehicle, or aircraft)

which cleared for--

on (Date)

as verified by export records.

AMS AUTHORIZED
(Inspector)

(Date)

(Inspector)

(Date)

I truly declare that the statements contained herein are true and
correct to the best of my knowledge and belief.

Entered or withdrawn by

FEDERAL EXPRESS CORP

EMP# (b) (6)

To the Inspector: The above-described goods shall be disposed of
AMS AUTHORIZED

For the Port Director

Received from the Port Director of the above CBP location the
merchandise described in this manifest for transportation and
delivery into the custody of the CBP officers at the port named
above, all packages in apparent good order except as noted hereon.
FEDERAL EXPRESS CORP

Emp# (b) (6)

Attorney or Agent of Carrier

CBP Form 7512 (03/08)



JANICE K. BREWER
GOVERNOR

Arizona Department of Corrections

1601 WEST JEFFERSON
PHOENIX, ARIZONA 85007
(602) 542-5497
www.azcorrections.gov



CHARLES L. RYAN
DIRECTOR

September 24 2010

David Thomas, DCM
FDA Investigations
Food and Drug Administration
Division of Import Operations and Policy
4605 East Elwood Street, Suite 402
Phoenix, Arizona 85040-1948

Dear Mr. Thomas:

Thank you for your professional assistance with the processing of this shipment. I am enclosing the original letter addressed to your agency and a copy of our Substance Control Registration Certificate.

Once again, thank you again for your assistance. Should you require additional information, please do not hesitate to contact me.

Sincerely,

Charles Flanagan
Deputy Director

cc: File

*Dave,
please do not hesitate to
contact me for any reason. I
greatly appreciate your assistance,
Charles*



JANICE K. BREWER
GOVERNOR

Arizona Department of Corrections

1601 WEST JEFFERSON
PHOENIX, ARIZONA 85007
(602) 542-5497
www.azcorrections.gov



CHARLES L. RYAN
DIRECTOR

September 24, 2010

David Thomas, DCM
FDA Investigations
Food and Drug Administration
Division of Import Operations and Policy
4605 East Elwood Street, Suite 402
Phoenix, Arizona 85040-1948

Re: Execution by Lethal Injection of Arizona Inmate
Jeffrey Timothy Landrigan #082157

Dear Mr. Thomas:


The purpose of this correspondence is to advise your agency of our intent to receive certain pharmaceutical products from Dream Pharma, Ltd. of London, England. We have placed the order with this company for the purpose of securing the necessary drugs for carrying out an execution warrant issued by the Arizona Supreme Court in the matter of State v. Jeffrey Timothy Landrigan, CR-90-0323 AP.

In order to proceed with the execution we must have the products ordered through Dream Pharma. Our DEA Registration number is: FA2203571 and it expires June 30, 2013. The execution is set by the court for October 26, 2010, and our agency is mandated to advise the court that it possesses the necessary chemicals for the lethal injection protocol as approved, no later than October 1, 2010.

Any steps your agency can take in attending to this shipment expeditiously would be of great assistance to our agency in its effort to abide by the court-ordered dates set by the court. Should your agency have any questions, do not hesitate to contact my office directly at (602) 542-5225 or after normal business hours through our command center at (602) 542-1212.

Thank you in advance for your professional assistance with the processing of this shipment.

Sincerely,



Charles L. Ryan
Director

cc: Charles Flanagan, Deputy Director
Robert Patton, Division Director, Offender Operations
Carson McWilliams, Warden, ASPC Florence

ARIZONA STATE PRISON - FLORENCE, CARSON
WARDEN
1305 BUTTE AVE.
P.O. BOX 629
FLORENCE, AZ 85232-0000-000



DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA2203571	06-30-2013	FEE EXEMPT
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
3,3N,4,5,	HOSPITAL/CLINIC	08-25-2010
ARIZONA STATE PRISON - FLORENCE, CARSON WARDEN 1305 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85232-0000		

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON D.C. 20537

This registration is only for use at Federal or State institutions.

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

Form DEA-223 (4/07)

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA2203571	06-30-2013	FEE EXEMPT
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
3,3N,4,5,	HOSPITAL/CLINIC	08-25-2010
ARIZONA STATE PRISON - FLORENCE, CARSON WARDEN 1305 BUTTE AVE. P.O. BOX 629 FLORENCE, AZ 85232-0000		

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON D.C. 20537

This registration is only for use at Federal or State institutions.

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA2203571	06-30-2013	Exempt

SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3 3N,4,5	HOSPITAL/CLINIC	08-25-2010

ARIZONA STATE PRISON - FLORENCE, CARSON A.,
WARDEN
1305 BUTTE AVE.
P.O. BOX 629
FLORENCE, AZ 85232 0000

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

This registration is only for use at Federal or State Institutions.

Sections 304 and 1008 (21 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IS NOT VALID AFTER THE EXPIRATION DATE.

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
FA2203571	06-30-2013	Exempt

SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3 3N,4,5	HOSPITAL/CLINIC	08-25-2010

ARIZONA STATE PRISON - FLORENCE, CARSON A.,
WARDEN
1305 BUTTE AVE.
P.O. BOX 629
FLORENCE, AZ 85232 0000

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

This registration is only for use at Federal or State Institutions.

Sections 304 and 1008 (21 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.

Form DEA-223 (05/04)

Dream Pharma Ltd.

176 Horn Lane, Acton, London, W3 6PJ
Tel: 020 8992 7000 Fax: 020 8992 7001
E-Mail: info@dreampharma.com

Invoice Details

Number: 2679INV

Date: 28-09-2010

Address:

Arizona State Prison Complex - Florence
Attention: Carson McWilliams, Warden
1305 Butte Avenue
Post Office Box 629
Florence, Arizona
85232
Tel: 602-364-3791

Delivery Address:

Arizona State Prison Complex - Florence
Attention: Carson McWilliams, Warden
1305 Butte Avenue
Post Office Box 629
Florence, Arizona
85232
602-364-3791

VAT no:

Purchase Order:

Currency: GBP - Pounds sterling

Heading: PHARMACEUTICALS NOT RESTRICTED

Order Details

Name/Description	Quantity	Price	Total
Thiopental Injection , powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's Batch No: AW6022 EXP: 05/14	(b) (4)	(4)	1180.5
POTASSIUM CHLORIDE 1.5GM 10ML INJ. PACKS OF 10 Batch No: 002067 EXP: 01/13	(b) (4)	(4)	279.9
Pancuronium Injection, pancuronium bromide 2 mg/mL, 2-mL amp packs of 10's Batch No: 949064 EXP: 11/11	(b) (4)	(4)	2642.85
Special delivery charges	1	150	150

Statement Details

Goods Total: 4253.25	Subtotal: 4528.25
Discount (%): 0	VAT (World Zero): 0.00
Delivery: 275	Previous Balance: 0
Insurance: 0	Total: 4528.25 GBP - Pounds sterling
	Payment Method: Prepayment Thank You

Shipping Details

Packing: (b) (4)	Gross Weight (Kg): (b) (4)
Tariff: 30049099	Net Weight (Kg): (b) (4)
Declarations: We certify that this invoice is true and correct.	Carrier: (b) (4)
	Matt Alavi, for Dream Pharma Ltd. 176 Horn Lane Acton, London W3 6PJ Tel: 020-8992-7000 Fax: 020-8992-7001

Damage, shortage or leakage must be notified in writing to ourselves within 3 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale. E&OE

Company Registration Number: 4637884 VAT No. GB805-5541-41
Director: M. Alavi

Page 1 of 1

FDA_08.18.11_000101

From: John Solomon [Solomon.John@doc.state.sc.us]

Sent: Wednesday, January 05, 2011 9:21 AM

To: Halpenny, Susan M

Subject: Na Thiopental

Good morning Susan,

The drugs have not been released as of 10:15 this morning. Have you heard anything this morning that is encouraging about this matter?

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

From: Halpenny, Susan M
Sent: Wednesday, January 05, 2011 10:20 AM
To: 'John Solomon'
Subject: RE: Na Thiopental
Good day,

Our Director of Imports, Domenic Veneziano, advised me yesterday that we may not receive the information he was preparing until today. I will let contact you once I have received this information and released the shipments.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

From: John Solomon [mailto:Solomon.John@doc.state.sc.us]
Sent: Wednesday, January 05, 2011 9:21 AM
To: Halpenny, Susan M
Subject: Na Thiopental

Good morning Susan,

The drugs have not been released as of 10:15 this morning. Have you heard anything this morning that is encouraging about this matter?

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

Bryce, John *

From: Thomas, David
Sent: Thursday, October 28, 2010 6:28 AM
To: Solis, Daniel
Cc: Strickland, Evanguel
Subject: Dream Pharma Shipments

Importance: High

Attachments: Dream Pharma FEI 3004744216.doc

Daniel:

I see 6 shipments of possible Lethal Injection Drugs from Dream Pharma beginning 6-28-10, in bold font. Shipments to POE PHX 2605, are observed as dates 9-29-10 and 10-25-10 for entries 574-0250322-1 and 574-0251126-5 respectively.



Dream Pharma
I 3004744216.doc

David Thomas, DCM
FDA Investigations
Phoenix, Office

Products Shipped:

Product Code	Description	GPI Code	Device Class	Last Shipment Date
60QLK28	Thiopental Sodium (Anesthetic)	DR - Drugs		10/25/2010
60QCY28	Thiopental Sodium (Anesthetic)	DR - Drugs		10/07/2010
65QLK25	Pancuronium Bromide (Relaxant)	DR - Drugs		09/29/2010
60QCN28	Thiopental Sodium (Anesthetic)	DR - Drugs		09/20/2010
60QIY28	Thiopental Sodium (Anesthetic)	DR - Drugs		07/27/2010
60QCR28	Thiopental Sodium (Anesthetic)	DR - Drugs		06/28/2010
63BIZ02	Albuterol Sulfate (Bronchodilator)	DR - Drugs		04/02/2010
61EIZ04	Budesonide (Anti-Asthmatic)	DR - Drugs		04/02/2010
63BAY02	Albuterol Sulfate (Bronchodilator)	DR - Drugs		03/27/2008
63BIY32	Formoterol Fumarate	DR - Drugs		12/20/2007
77KCO	Inhaler, Nasal	DE - Devices	1	12/20/2007
62TCE02	Lansoprazole (Anti-Secretory)	DR - Drugs		06/22/2007
55PP55	Silica Gel (Pharmaceutic Necessity)	DR - Drugs		06/19/2007
55PY55	Silica Gel (Pharmaceutic Necessity)	DR - Drugs		06/11/2007
62FBO20	Iodine (Anti-Infective, Topical)	DR - Drugs		04/24/2006
61EIIY99	Anti-Asthmatic, N.E.C.	DR - Drugs		03/18/2006
61ECQ99	Anti-Asthmatic, N.E.C.	DR - Drugs		01/16/2006
62CCK16	Diazoxide (Anti-Hypertensive)	DR - Drugs		10/10/2005
62CCY16	Diazoxide (Anti-Hypertensive)	DR - Drugs		09/17/2004

Firm Services vv2.1.02 July 15, 2010 (fdsul09623.fda.gov) | Copyright 2008 | U.S. Food and Drug Administration

From: Halpenny, Susan M
Sent: Wednesday, December 01, 2010 2:35 PM
To: 'John Solomon'
Subject: RE: shipment delay FDA entry # 112967344464
Good afternoon,

I apologize for the delay but our Director of Import Operations has been in meetings this week on this subject, and I have not received any word back as yet. I will contact you as soon as hear something.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

From: John Solomon [mailto:Solomon.John@doc.state.sc.us]
Sent: Wednesday, December 01, 2010 2:03 PM
To: Halpenny, Susan M
Subject: shipment delay FDA entry # 112967344464

Hello Susan,

I checked the tracking on the shipment and find it is still delayed. Is there any movement toward a decision on who has jurisdiction (FDA or DEA)? Is there agreement on a time for a decision to be made? If this is not resolved soon we may be exchanging Christmas cards.

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

Bryce, John *

From: Thomas, David
Sent: Wednesday, October 27, 2010 3:37 PM
To: Strickland, Evanguel
Subject: Completed conference with Dan. Out of office at 3:30 PM

David Thomas, DCM
FDA Investigations
Phoenix, Office

From: Solis, Daniel
Sent: Wednesday, October 27, 2010 3:12 PM
To: Thomas, David
Cc: Strickland, Evanguel
Subject: RE: First entry scenario, complete

Thanks you. This is good.

Is there one for Entry # 574-0251126-5?

From: Thomas, David
Sent: Wednesday, October 27, 2010 3:08 PM
To: Solis, Daniel
Cc: Strickland, Evanguel
Subject: First entry scenario, complete

Daniel:

This is complete for the first entry.

Entry 574-0250322-1

September 24, 2010 Mr. Charles Flanagan, Deputy Director Arizona Department of Corrections (602) 542-3611 contacted CSO David Thomas from the FDA Office in Phoenix stating he wanted to import a shipment of drugs from overseas and asked the procedures. Mr. Flanagan was directed to U.S.C.B.P. for a list of brokers to choose from to initiate an importation process.

September 27 2010 Arizona Customs Brokers, ACB, was chosen by AZ DOC.

ACB sent PHX-RP imports partial entry information which included letter of intent, DEA certificate, and list of products. Products were Thiopental Sodium, Potassium Chloride, and Pancuronium Bromide. ACB also advised PHX-PR the entry 574-0250322-1 would be transmitted wheels up from the U.K. An email was sent to DIOP and supervision immediately notifying of the proposed import with attached documentation of the information received from ACB. Entry review of manufacturer, Dream Pharma Ltd. of London, England revealed the manufacturer was FDA registered for certain drugs, but not the drugs being imported.

1. FDA Investigator was provided with an official letter from the Arizona Department of Corrections stating this shipment of drugs was warranted by the Arizona Supreme Court (State v. Jeffrey Timothy Landrigan, CR-90-0323 AP).
2. Manufacturer Dream Pharma has several FDA registration numbers for drugs; however not for

the aforementioned being imported.

3. Arizona Department of Corrections also has a DEA registration number -FA2203571.

September 29, 2010 entry arrived Port of Entry Phoenix via Memphis, TN.

PHX-RP received email notification from DIOP that entry was available for release. Upon arrival that afternoon, product was confirmed for labeling, count and amount with AZ DOC personnel in accompaniment of the CSO. Product was FDA released, then taken into custody by AZ DOC after the inspection.

David Thomas, DCM
FDA Investigations
Phoenix, Office

From: Solis, Daniel
Sent: Wednesday, October 27, 2010 2:55 PM
To: Thomas, David
Cc: Strickland, Evanguel
Subject: RE: Scenario Initial AZ DOC entry

From: Halpenny, Susan M
Sent: Wednesday, December 01, 2010 2:35 PM
To: 'John Solomon'
Subject: RE: shipment delay FDA entry # 112967344464
Good afternoon,

I apologize for the delay but our Director of Import Operations has been in meetings this week on this subject, and I have not received any word back as yet. I will contact you as soon as hear something.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

From: John Solomon [mailto:Solomon.John@doc.state.sc.us]
Sent: Wednesday, December 01, 2010 2:03 PM
To: Halpenny, Susan M
Subject: shipment delay FDA entry # 112967344464

Hello Susan,

I checked the tracking on the shipment and find it is still delayed. Is there any movement toward a decision on who has jurisdiction (FDA or DEA)? Is there agreement on a time for a decision to be made? If this is not resolved soon we may be exchanging Christmas cards.

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

Bryce, John *

From: Thomas, David
Sent: Wednesday, September 29, 2010 9:57 AM
To: Verbeten, John E. (ORA); Notzon, Stella; Batista, Huascar R; Bormel, Frances Gail; Anderson, Kathleen R
Cc: Solis, Daniel; Strickland, Evanguel
Subject: Entry 574-0250322-1: Lethal Injection Pharmacology
Importance: High
Attachments: 57402503221.pdf



57402503221.pdf
f (630 KB)

John:

The above entry of Lethal Injection pharmacology has been transmitted for the purpose of execution of a Arizona prisoner.

The issue involves 3 products from manufacturer Dream Pharma, London, UK, FEI 3004744216. Product 1) Thiopental Sodium NDC 000703-2556, product 2) Pancuronium Bromide NDC 000074-4645, and product 3) Potassium Chloride Injectable NDC 000469-6520 do not appear to have valid DRLS numbers for the manufacturer. However, Dream Pharma is registered under the aforementioned FEI.

Arizona Department of Corrections Director, Charles Ryan, 602-542-5225, has related in previous correspondence that his agency must have these products in hand today to be accountable to the Arizona Supreme Court by September 30, 2010 for the intended purpose above. (see attached AZ DOC correspondence)

Currently the product is being trucked into Phoenix from Los Angeles. (b) (4) mistakenly routed the product from Memphis, TN to Los Angeles, CA instead of the planned flight to Phoenix, AZ.

Lastly, I have attached the entry documentation and held the entry in my inbox, pending Agency approval of a release.

May I hear from you soon,

David Thomas, DCM
FDA Investigations
Phoenix, Office

-----Original Message-----

From: Verbeten, John E. (ORA)
Sent: Wednesday, September 29, 2010 3:54 AM
To: Notzon, Stella; Batista, Huascar R; Bormel, Frances Gail; Anderson, Kathleen R
Cc: Thomas, David; Solis, Daniel
Subject: Re: Lethal Injection Pharmacology

(b) (5)

----- Original Message -----

From: Notzon, Stella
To: Batista, Huascar R; Bormel, Frances Gail; Anderson, Kathleen R
Cc: Thomas, David; Solis, Daniel; Verbeten, John E. (ORA)
Sent: Mon Sep 27 13:06:53 2010
Subject: FW: Lethal Injection Pharmacology

Huascar, et.al,

(b) (5)

Stella

-----Original Message-----

From: Thomas, David
Sent: Monday, September 27, 2010 11:33 AM
To: Notzon, Stella
Cc: Strickland, Evanguel; Solis, Daniel
Subject: FW: Lethal Injection Pharmacology
Importance: High

Stella:

FYI

Dave Thomas
FDA Imports
Phoenix, AZ

-----Original Message-----

From: Thomas, David
Sent: Monday, September 27, 2010 8:23 AM
To: Taube, Anthony C
Cc: Strickland, Evanguel; Solis, Daniel; 'DEAN, MICHAEL K'; 'CHARLES FLANAGAN'
Subject: Lethal Injection Pharmacology
Importance: High

Prior Notice Center Director, Anthony Taube:

RE: Lethal Injection pharmacology:

Sir:

I have an entry of 3 components of a lethal injection, 1) Thiopental, 2) Pancuronium, 3) Potassium Chloride departing London this afternoon, destination Memphis with Port of Entry 2605, Phoenix. As of this communication, no entry has been made.

These pharmaceuticals are needed to carry out an execution here in Arizona, and are not for public consumption. Attached is Please find attached explanatory documentation and DEA registration for the Arizona Corrections facility.

Lastly, should I be advising anyone else?

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office

Charles:

We are in receipt of your communication and PDF attachments. I have CC'd my Supervisor, Mr. Strickland, and our Imports Director Mr. Solis for their review.

David Thomas, DCM
FDA Investigations
Phoenix, Office

-----Original Message-----

From: CHARLES FLANAGAN [mailto:CFLANAG@azcorrections.gov]
Sent: Friday, September 24, 2010 5:04 PM
To: Thomas, David
Subject: Pharmaceuticals from Dream Pharma, LTD. of London, England

Good Afternoon Mr. Thomas:

Thank you so much for your assistance with this matter. I have attached to this email a copy of the correspondence what will be shipped with the pharmaceuticals. It also includes the Department of Corrections' "Substance Control Registration Certificate". The second attachment is a list of the items that will be shipped to our facility; to include quantities purchased and the last attachment is the revised DEA Registration which includes certification for Schedule 2 drugs.

Once again, thank you again for your assistance. Should you require additional information, please do not hesitate to contact me. Here is my information:

Charles Flanagan
Deputy Director
Arizona Department of Corrections
1601 W. Jefferson - MC 445
Phoenix, Arizona 85007
(602) 542-3611 Office
(602) 377-5334 Cell
(602) 364-0601 Fax
cflanag@azcorrections.gov

From: John Solomon [Solomon.John@doc.state.sc.us]

Sent: Tuesday, December 07, 2010 7:14 AM

To: Halpenny, Susan M

Subject: clearance delay

Good morning Susan,

It has been a month since the FDA has chosen to delay delivery of a package sent from England to the South Carolina Department of Corrections. From our last conversation I understand there is a discussion regarding "jurisdiction" between the FDA and the DEA. If it does not appear that there will be a solution to this stalemate in the near future (think next 24 hours) can you direct me to someone who might be able to help expedite a decision?

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0250322-1

Notice Number: 1

September 29, 2010

Consignee:

Arizona State Prison Complex
1305 Butte Ave
Florence, AZ 85232

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4);

Date Received: September 29, 2010

Arrival Date: September 28, 2010

Filer of Record: Arizona Customs Brokers, Phoenix, AZ 85040

Importer of Record: Arizona Department Of Correction, Phoenix, AZ 85007-3002

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
001/001	THIOPENTAL SODIUM 500 MG	(b) (4)	Released 09-29-2010
002/001	PANCURONIUM INJECTION		Line Split
002/001A	PANCURONIUM BROMIDE		Released 09-29-2010
002/001B	POTASSIUM CHLORIDE INJECTIBLE		Released 09-29-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0250322-1. Any status changes are reflected in the Line summary and line detail sections.

David C. Thomas, Investigator
U.S. Food & Drug Administration
51 W. 3rd Street, Suite E-265
Tempe, AZ 85281

(480) 829-7396 ext. 12
(480) 829-7677 (FAX)
DAVID.THOMAS@FDA.HHS.GOV

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: SAW

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0250322-1

Notice Number: 1

September 29, 2010

Filer:

Arizona Customs Brokers
2153 East Jones Ave
Phoenix, AZ 85040

Attention:

(b) (6)

Broker Box:

(b) (4)

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4)

Date Received: September 29, 2010

Arrival Date: September 28, 2010

Importer of Record: Arizona Department Of Correction, Phoenix, AZ 85007-3002

Consignee: Arizona State Prison Complex, Florence, AZ 85232

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
001/001	THIOPENTAL SODIUM 500 MG	(b) (4)	Released 09-29-2010
002/001	PANCURONIUM INJECTION		Line Split
002/001A	PANCURONIUM BROMIDE		Released 09-29-2010
002/001B	POTASSIUM CHLORIDE INJECTIBLE		Released 09-29-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0250322-1. Any status changes are reflected in the Line summary and line detail sections.

David C. Thomas, Investigator
U.S. Food & Drug Administration
51 W. 3rd Street, Suite E-265
Tempe, AZ 85281

(480) 829-7396 ext. 12
(480) 829-7677 (FAX)
DAVID.THOMAS@FDA.HHS.GOV

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: SAW

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0250322-1

Notice Number: 1

September 29, 2010

Importer:

Arizona Department Of Correction
1601 W Jefferson St
Phoenix, AZ 85007-3002

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4)

Date Received: September 29, 2010

Arrival Date: September 28, 2010

Filer of Record: Arizona Customs Brokers, Phoenix, AZ 85040

Consignee: Arizona State Prison Complex, Florence, AZ 85232

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
001/001	THIOPENTAL SODIUM 500 MG	(b) (4)	Released 09-29-2010
002/001	PANCURONIUM INJECTION		Line Split
002/001A	PANCURONIUM BROMIDE		Released 09-29-2010
002/001B	POTASSIUM CHLORIDE INJECTIBLE		Released 09-29-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0250322-1. Any status changes are reflected in the Line summary and line detail sections.

David C. Thomas, Investigator
U.S. Food & Drug Administration
51 W. 3rd Street, Suite E-265
Tempe, AZ 85281

(480) 829-7396 ext. 12
(480) 829-7677 (FAX)
DAVID.THOMAS@FDA.HHS.GOV

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: SAW

From: Halpenny, Susan M
Sent: Thursday, December 09, 2010 1:38 PM
To: 'John Solomon'
Subject: RE: status
Good day Dr. Solomon,

I have asked for an update on the status of your shipment from our Center for Imports but unfortunately they do not have any updates to give me. I will continue to check on this daily.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

From: John Solomon [mailto:Solomon.John@doc.state.sc.us]
Sent: Thursday, December 09, 2010 6:51 AM
To: Halpenny, Susan M
Subject: status

Good morning Susan,

May we have a status report with particular attention as to why the FDA continues to intervene in this particular drug purchase? Also, the delay now borders on being excessive. Does anyone have any idea when a decision will be rendered to release the shipment? Thank you for continuing assistance.

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

From: John Solomon [Solomon.John@doc.state.sc.us]

Sent: Thursday, December 09, 2010 6:51 AM

To: Halpenny, Susan M

Subject: status

Good morning Susan,

May we have a status report with particular attention as to why the FDA continues to intervene in this particular drug purchase? Also, the delay now borders on being excessive. Does anyone have any idea when a decision will be rendered to release the shipment? Thank you for continuing assistance.

John

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0250322-1

Notice Number: 1

September 29, 2010

Consignee:

Arizona State Prison Complex
1305 Butte Ave
Florence, AZ 85232

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4);

Date Received: September 29, 2010

Arrival Date: September 28, 2010

Filer of Record: Arizona Customs Brokers, Phoenix, AZ 85040

Importer of Record: Arizona Department Of Correction, Phoenix, AZ 85007-3002

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
001/001	THIOPENTAL SODIUM 500 MG	(b) (4)	Released 09-29-2010
002/001	PANCURONIUM INJECTION		Line Split
002/001A	PANCURONIUM BROMIDE		Released 09-29-2010
002/001B	POTASSIUM CHLORIDE INJECTIBLE		Released 09-29-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0250322-1. Any status changes are reflected in the Line summary and line detail sections.

David C. Thomas, Investigator
U.S. Food & Drug Administration
51 W. 3rd Street, Suite E-265
Tempe, AZ 85281

(480) 829-7396 ext. 12
(480) 829-7677 (FAX)
DAVID.THOMAS@FDA.HHS.GOV

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: SAW

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0250322-1

Notice Number: 1

September 29, 2010

Filer:

Arizona Customs Brokers
2153 East Jones Ave
Phoenix, AZ 85040

Attention:

(b) (6)

Broker Box:

(b) (4)

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4)

Date Received: September 29, 2010

Arrival Date: September 28, 2010

Importer of Record: Arizona Department Of Correction, Phoenix, AZ 85007-3002

Consignee: Arizona State Prison Complex, Florence, AZ 85232

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
001/001	THIOPENTAL SODIUM 500 MG	(b) (4)	Released 09-29-2010
002/001	PANCURONIUM INJECTION		Line Split
002/001A	PANCURONIUM BROMIDE		Released 09-29-2010
002/001B	POTASSIUM CHLORIDE INJECTIBLE		Released 09-29-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0250322-1. Any status changes are reflected in the Line summary and line detail sections.

David C. Thomas, Investigator
U.S. Food & Drug Administration
51 W. 3rd Street, Suite E-265
Tempe, AZ 85281

(480) 829-7396 ext. 12
(480) 829-7677 (FAX)
DAVID.THOMAS@FDA.HHS.GOV

Notice Prepared For: The District Director, U.S. Food and Drug Administration

Notice Prepared By: SAW

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0250322-1

Notice Number: 1

September 29, 2010

Importer:

Arizona Department Of Correction
1601 W Jefferson St
Phoenix, AZ 85007-3002

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4)

Date Received: September 29, 2010

Arrival Date: September 28, 2010

Filer of Record: Arizona Customs Brokers, Phoenix, AZ 85040

Consignee: Arizona State Prison Complex, Florence, AZ 85232

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
001/001	THIOPENTAL SODIUM 500 MG	(b) (4)	Released 09-29-2010
002/001	PANCURONIUM INJECTION		Line Split
002/001A	PANCURONIUM BROMIDE		Released 09-29-2010
002/001B	POTASSIUM CHLORIDE INJECTIBLE		Released 09-29-2010

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0250322-1. Any status changes are reflected in the Line summary and line detail sections.

David C. Thomas, Investigator
U.S. Food & Drug Administration
51 W. 3rd Street, Suite E-265
Tempe, AZ 85281

(480) 829-7396 ext. 12
(480) 829-7677 (FAX)
DAVID.THOMAS@FDA.HHS.GOV

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: SAW

From: John Solomon [Solomon.John@doc.state.sc.us]

Sent: Monday, December 20, 2010 9:29 AM

To: Halpenny, Susan M

Cc: David Tatarsky

Subject: Delay of Shipment

Good morning Susan,

The FDA imposed delay is an increasing concern to us. Is there anyone who can give us a reasonable explanation for the FDA's decision to stop the shipment to South Carolina? For the FDA to stop the shipment and then refuse to communicate the reason for its decision is unconscionable. Your assistance with this matter is appreciated.

John

Copy to David Tatarsky – General Counsel for the Department of Corrections

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

From: Halpenny, Susan M
Sent: Monday, December 20, 2010 10:25 AM
To: 'John Solomon'
Cc: David Tatarsky
Subject: RE: Delay of Shipment
Good day,

I have not heard anything from our Director of Import Operations and Policy at this time. If you would like to follow up with him, our Director is Domenic Veneziano and his phone number is (301) 594-3849. You can also contact the office of our FDA commissioner, Margaret Hamburg at (301) 796-5000.

Susan M. Halpenny
Supervisory Investigator
FDA, New Orleans District, Imports
Voice (901) 333-3521
Fax (901) 333-3576

From: John Solomon [mailto:Solomon.John@doc.state.sc.us]
Sent: Monday, December 20, 2010 9:29 AM
To: Halpenny, Susan M
Cc: David Tatarsky
Subject: Delay of Shipment

Good morning Susan,

The FDA imposed delay is an increasing concern to us. Is there anyone who can give us a reasonable explanation for the FDA's decision to stop the shipment to South Carolina? For the FDA to stop the shipment and then refuse to communicate the reason for its decision is unconscionable. Your assistance with this matter is appreciated.

John

Copy to David Tatarsky – General Counsel for the Department of Corrections

John P. Solomon, Ph.D., MBA
Director of Health Services
South Carolina Department of Corrections
4444 Broad River Rd.
Columbia, SC 29210
(Tele) 803-896-1995
(Fax) 803-896-1999

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0251126-5

Notice Number: 1

January 7, 2011

Filer:

Arizona Customs Brokers
2153 East Jones Ave
Phoenix, AZ 85040

Attention:

(b) (6)

Broker Box:

(b) (4)

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4);

Date Received: October 25, 2010

Arrival Date: October 26, 2010

Importer of Record: Arizona Department Of Correction, Phoenix, AZ 85007-3002

Consignee: Arizona State Prison Complex, Florence, AZ 85232

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
* 001/001	THIOPENTAL SODIUM, POWDER	(b) (4)	Released 01-06-2011

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0251126-5. Any status changes are reflected in the Line summary and line detail sections.

CORRESPONDENCE

Line ACS/FDA	Product Description
001/001	THIOPENTAL SODIUM, POWDER

Comments : FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity or any other characteristics.

Ruben Delagarza, Compliance Officer
(Region/District)
U.S. Food and Drug Administration
222 W. 6th St., Suite 700

(310) 971-2297
(310) 971-2363 (FAX)
laimports@FDA.HHS.GOV

Notice of FDA Action
Entry Number: 574-0251126-5

Notice Number: 1
Page: 2

San Pedro, CA 90731

LINES RELEASED

Line ACS/FDA	Product Description
--------------	---------------------

001/001	THIOPENTAL SODIUM, POWDER
---------	---------------------------

Ruben Delagarza, Compliance Officer
(Region/District)
U.S. Food and Drug Administration
222 W. 6th St., Suite 700
San Pedro, CA 90731

(310) 971-2297
(310) 971-2363 (FAX)
laimports@FDA.HHS.GOV

These products are released. This notice does not constitute assurance that the product released complies with all provisions of the Food, Drug, and Cosmetic Act, or other related Acts, and does not preclude action should the product later be found violative.

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: SAW

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0251126-5

Notice Number: 1

January 7, 2011

Importer:

Arizona Department Of Correction
1601 W Jefferson St
Phoenix, AZ 85007-3002

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4)

Date Received: October 25, 2010

Arrival Date: October 26, 2010

Filer of Record: Arizona Customs Brokers, Phoenix, AZ 85040

Consignee: Arizona State Prison Complex, Florence, AZ 85232

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
* 001/001	THIOPENTAL SODIUM, POWDER	(b) (4)	Released 01-06-2011

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0251126-5. Any status changes are reflected in the Line summary and line detail sections.

CORRESPONDENCE

Line ACS/FDA	Product Description
001/001	THIOPENTAL SODIUM, POWDER

Comments : FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity or any other characteristics.

Ruben Delagarza, Compliance Officer
(Region/District)
U.S. Food and Drug Administration
222 W. 6th St., Suite 700

(310) 971-2297
(310) 971-2363 (FAX)
laimports@FDA.HHS.GOV

Notice of FDA Action
Entry Number: 574-0251126-5

Notice Number: 1
Page: 2

San Pedro, CA 90731

LINES RELEASED

Line ACS/FDA	Product Description
--------------	---------------------

001/001	THIOPENTAL SODIUM, POWDER
---------	---------------------------

Ruben Delagarza, Compliance Officer
(Region/District)
U.S. Food and Drug Administration
222 W. 6th St., Suite 700
San Pedro, CA 90731

(310) 971-2297
(310) 971-2363 (FAX)
laimports@FDA.HHS.GOV

These products are released. This notice does not constitute assurance that the product released complies with all provisions of the Food, Drug, and Cosmetic Act, or other related Acts, and does not preclude action should the product later be found violative.

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: SAW

United States Food and Drug Administration

Los Angeles District Office

Notice of FDA Action

Entry Number: 574-0251126-5

Notice Number: 1

January 7, 2011

Consignee:

Arizona State Prison Complex
1305 Butte Ave
Florence, AZ 85232

>

<

Port of Entry: 2605, Phoenix, AZ

Carrier: (b) (4)

Date Received: October 25, 2010

Arrival Date: October 26, 2010

Filer of Record: Arizona Customs Brokers, Phoenix, AZ 85040

Importer of Record: Arizona Department Of Correction, Phoenix, AZ 85007-3002

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
* 001/001	THIOPENTAL SODIUM, POWDER	(b) (4)	Released 01-06-2011

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 574-0251126-5. Any status changes are reflected in the Line summary and line detail sections.

CORRESPONDENCE

Line ACS/FDA	Product Description
001/001	THIOPENTAL SODIUM, POWDER

Comments : FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity or any other characteristics.

Ruben Delagarza, Compliance Officer
(Region/District)
U.S. Food and Drug Administration
222 W. 6th St., Suite 700

(310) 971-2297
(310) 971-2363 (FAX)
laimports@FDA.HHS.GOV

Notice of FDA Action
Entry Number: 574-0251126-5

Notice Number: 1
Page: 2

San Pedro, CA 90731

LINES RELEASED

Line ACS/FDA	Product Description
001/001	THIOPENTAL SODIUM, POWDER
Ruben Delagarza, Compliance Officer (Region/District) U.S. Food and Drug Administration 222 W. 6th St., Suite 700 San Pedro, CA 90731	(310) 971-2297 (310) 971-2363 (FAX) laimports@FDA.HHS.GOV

These products are released. This notice does not constitute assurance that the product released complies with all provisions of the Food, Drug, and Cosmetic Act, or other related Acts, and does not preclude action should the product later be found violative.

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: SAW



DEPARTMENT OF HEALTH AND HUMAN SERVICE

Food and Drug Administration
New Orleans District
Import Operations
959 Ridgeway Loop, Suite 100
Memphis, Tn. 38120

Telephone: (901) 333-3520
FAX: (901) 333-3579

January 7, 2011

UNITED PARCEL SERVICE
Delivery Signature Requested

John P. Solomon, PhD, MBA
Director of Health Services
South Carolina Department of Corrections
Kirkland Correctional Institution-Pharmacy
4344 Broad River Road
Columbia, South Carolina 29210-4010

RE: Entry Number 112-673446-4

Dear Mr. Solomon:

This letter provides the status of Entry Number 112-9673446-4, consisting of (b) (4) vial packets, each vial containing 500 mg of Thiopental Sodium. FDA received documentation for this shipment and verified it is destined for a state correctional facility.

FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity or any other characteristics.

Sincerely,

Patricia K. Schafer
Patricia K. Schafer
Acting District Director
New Orleans District Office

Enclosure: FDA Notice of Action

Bryce, John *

From: Solis, Daniel
Sent: Wednesday, October 27, 2010 1:44 PM
To: Thomas, David; Strickland, Evanguel
Subject: FW: Entry number of 9/29/10 shipment

This is what I have so far. More details I am working on:

- September 24, 2010 = Charles Flanagan, Deputy Director Arizona Department of Corrections (602) 542-3611 contacted CSO from the FDA Office in Phoenix, Az, David Thomas, regarding shipment under Entry 574-0251126-5. This initial email was to inform Phoenix of the incoming shipment from London (Dream Pharma, Ltd. Of London, England) destination Memphis with Port of Entry 2605, Phoenix, Az.
- Shipment was of 3 chemical components: Sodium Thiopental, Pancuronium Bromide and Potassium Chloride
- FDA Investigator was provided with an official letter from the Arizona Department of Corrections stating this shipment of drugs was warranted by the Arizona Supreme Court (State v. Jeffrey Timothy Landrigan, CR-90-0323 AP).
- In order to execute the warrant, the Arizona Department of Corrections, needed the products from dream Pharma. (Dream Pharma has an FDA registration number and has drugs and devices reg and listing).
- Arizona Department of Corrections also has a DEA registration number FA2203571.

From: Roh, Mark S
Sent: Wednesday, October 27, 2010 1:39 PM
To: Solis, Daniel
Subject: Re: Entry number of 9/29/10 shipment

I'm anxiously awaiting your summary report.
Mark Roh
Pacific Regional Director
Office phone - 510-637-3960
Mobile phone - 510-590-3001

From: Solis, Daniel
Sent: Wednesday, October 27, 2010 03:51 PM
To: Veneziano, Domenic J.
Cc: Elder, David K.; Rogers, Michael; Roh, Mark S
Subject: RE: Entry number of 9/29/10 shipment

I just finished talking to Charles Flanagan from the Arizona Dept. of Corrections. He provided me with some insight. You can't wait for my summary report or we can have a quick phone con on what I found out.

From: Veneziano, Domenic J.
Sent: Wednesday, October 27, 2010 12:26 PM
To: Solis, Daniel
Cc: Elder, David K.; Rogers, Michael; Roh, Mark S
Subject: Entry number of 9/29/10 shipment

Dan the entry number for the LA shipment is 574-0250322-1/1/1

Domenic J. Veneziano
CDR U.S. Public Health Service
Director, Division of Import Operations and Policy
Work: (301) 443-6553
FAX: (301) 594-0413
Cell: (240) 888-9316

United States Food and Drug Administration

New Orleans District Office

Notice of FDA Action

Entry Number: 112-9938358-2

Notice Number: 2

January 6, 2011

Importer:

(b) (4)

>

<

Port of Entry: 2095, FedEx - Memphis, Memphis, TN

Carrier: (b) (4)

Date Received: November 24, 2010

Arrival Date: November 19, 2010

Filer of Record: FEDEX Trade Networks Transport and Brokerage, Memphis, TN 38125

Consignee: (b) (4)

COMMERCIAL ENTRY CLOSED

Summary of Current Status of Individual Lines

Line ACS/FDA	Product Description	Quantity	Current Status
* 001/001	688760418962 THIOPENTAL	(b) (4)	Released 01-06-2011

* = Status change since the previous notice. Read carefully the sections which follow for important information regarding these lines.

@ = Consignee ID

This is the final notice concerning entry 112-9938358-2. Any status changes are reflected in the Line summary and line detail sections.

CORRESPONDENCE

Line ACS/FDA	Product Description
001/001	688760418962 THIOPENTAL

Comments : FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity or any other characteristics.

Randy N. Boling, Compliance Officer (Region/District)
U.S. Food and Drug Administration
959 Ridgeway Loop Road, Suite 100
Memphis, TN 38120-4042

(901) 333-3537
(901) 333-3579 (FAX)
RANDY.BOLING@FDA.HHS.GOV

LINES RELEASED

Line ACS/FDA	Product Description
--------------	---------------------

001/001	688760418962 THIOPENTAL
---------	-------------------------

Randy N. Boling, Compliance Officer (Region/District)	(901) 333-3537
U.S. Food and Drug Administration	(901) 333-3579 (FAX)
959 Ridgeway Loop Road, Suite 100	RANDY.BOLING@FDA.HHS.GOV
Memphis, TN 38120-4042	

These products are released. This notice does not constitute assurance that the product released complies with all provisions of the Food, Drug, and Cosmetic Act, or other related Acts, and does not preclude action should the product later be found violative.

Notice Prepared For: The District Director, U.S. Food and Drug Administration
Notice Prepared By: LPW

DEPARTMENT OF THE TREASURY
UNITED STATES CUSTOMS SERVICEForm Approved
OMB No. 1515-0069

ENTRY/IMMEDIATE DELIVERY

ABI CERTIFIED

FEDEX TRADE NETWORKS
TRANSPORT & BROKERAGE, INC.

AIR EXPRESS

TEL: (901) 752-3000

19 CFR 142.3, 142.16, 142.22, 142.24

1. ARRIVAL DATE 111910	2. ELECTED ENTRY DATE	3. ENTRY TYPE CODE/NAME 01	4. ENTRY NUMBER 112-9938358-2
5. PORT 2095	6. SINGLE TRANS. BOND	7. BROKER/IMPORTER FILE NUMBER (b) (4)	
	8. CONSIGNEE NUMBER (b) (4)	9. IMPORTER NUMBER (b) (4)	
10. ULTIMATE CONSIGNEE NAME (b) (4)		11. IMPORTER OF RECORD NAME (b) (4)	
12. CARRIER CODE (b) (4)	13. VOYAGE/FLIGHT/TRIP (b) (4)	14. LOCATION OF GOODS-CODE(S)/NAME(S) (b) (4)	
15. VESSEL CODE/NAME			
16. U.S. PORT OF UNLADING 2095	17. MANIFEST NUMBER	18. G.O. NUMBER	19. TOTAL VALUE 15575
20. DESCRIPTION OF MERCHANDISE PHARMACEUTICALS NOT RESTRICTED			
21. IT/BL/AWB CODE M H	22. IT/BL/AWB NO. TOTAL (b) (4)	23. MANIFEST QUANTITY (b) (4)	24. H.S. NUMBER 3004.90.9190
			25. COUNTRY OF ORIGIN GB
			26. MANUFACTURER ID. GBDREPHA176LON

27. CERTIFICATION

I hereby make application for entry/immediate delivery. I certify that the above information is accurate, the bond is sufficient, valid, and current, and that all requirements of 19 CFR Part 142 have been met.

SIGNATURE OF APPLICANT

(b) (6)

PHONE NO.

(b) (4)

DATE

11/24/10

29. BROKER OR OTHER GOVT. AGENCY USE

28. CUSTOMS USE ONLY

☐ OTHER AGENCY ACTION REQUIRED, NAMELY:

☐ CUSTOMS EXAMINATION REQUIRED.

☐ ENTRY REJECTED, BECAUSE:
DELIVERY
AUTHORIZED:

SIGNATURE

DATE

Dream Pharma Ltd.

176 Horn Lane, Acton, London, W3 6PJ
Tel: 020 8992 7000 Fax: 020 8992 7001
E-Mail: info@dreampharma.com

Invoice Details

Number: 2727INV

Date: 19-11-2010

Address:

(b) (4)

Delivery Address:

(b) (4)

Tel: (b) (4)

(b) (4)

VAT no:

Currency: USD - US Dollar

Purchase Order:

Heading: PHARMACEUTICALS NOT RESTRICTED

Order Details

Name/Description	Quantity	Price	Total
Thiopental Injection , powder for reconstitution, thiopental sodium, 500-mg vial packs of 25's Batch No: AW6022 EXP: 05/14	(b) (4)		14700

Statement Details

Goods Total: 14700.00	Subtotal: 15575.00
Discount (%): 0	VAT (World Zero): 0.00
Delivery: 875	Previous Balance: 0
Insurance: 0	Total: 15575.00 USD - US Dollar
	Payment Method: Prepayment Thank You

Shipping Details

Packing: (b) (4)	Gross Weight (Kg): (b) (4)
Tariff: 30049099	Net Weight (Kg): (b) (4)
Declarations: We certify that this invoice is true and correct.	Carrier: (b) (4)
	Matt Alavi, for Dream Pharma Ltd.

DREAM PHARMA LTD
176 Horn Lane
Acton, London W3 6PJ
Tel: 020-8992-7000
Fax: 020-8992-7001

Damage, shortage or leakage must be notified in writing to ourselves within 3 days. Non-Delivery within 14 days. Goods remain the property of Dream Pharma Ltd. Until full payment has been received. Subject to our standard conditions of sale. E&OE

Company Registration Number: (b) (4) VAT No. (b) (4)

Director: M. Alavi

Page 1 of 1

(b) (4) Manifest report

SHP DT 19-NOV-2010 SNDR# (b) (4) METER THERMAL ☒ RECIP#
AB (b) (4) PH (b) (4) RECIPENT PH (b) (4) SIN# (b) (4)
NAME Matt Alavi NAME
COMP Dream Pharma Ltd. COMP
ADD1 176 Horn Lane ADD1
ADD2 ADD2
CITY ACTON, LONDON CITY
ST/PV CTRY GB POSTAL W36PJ ST/PV
REF Pharmaceuticals Not Restricted
PKGS (b) (4) WEIGHT (b) (4) K/L K DIM WEIGHT K/L K
DESC PHARMACEUTICALS NOT RESTRICTED EN CD 30049099 COM GB CUST VAL 0 EXP DT EXP LIC

(b) (4)

MPS shipment

Package # Package Weight

(b) (4)

IMPORTANT - Treat as the Manifest Copy of the Air Waybill
*** Please give this (b) (4) Manifest report to the (b) (4) courier ***

Master Nbr: 4577414 Software: FWS0716

LOCATION MEM NEW INTERNATIONAL AIRBILL ENTRY ENT# 112-9938358-2

(b) (4)


NAME MATT ALAVI
COMP DREAM PHARMA LTD.
ADD1 176 HORN LANE
ADD2
CITY ACTON, LONDON
ST/PV CNTRY GB POSTAL W36PJ

NAME
COMP
ADD1
ADD2
CITY
ST/PV

(b) (4)

(b) (4)

PKGS	K/L	WEIGHT	COM	CARR	VAL	CUSTOMS	VAL	EX	LIC	HDLG	UNITS
(b) (4)	K	(b) (4)	GB	USD			15575.00				
DESC: PHARMACEUTICALS NOT RESTRICTED											



01-22-2010 12:00pm

From

(b) (4)

(b) (4)

T-859 P.001/001 F-698

(b) (4)

Approved through 12/31/95. OMB NO. 1545-0047
See back of form for Paperwork Reduction Act Notice.DEPARTMENT OF THE TREASURY
UNITED STATES CUSTOMS SERVICEIMPORTER ID
INPUT RECORD

FILL 2A OR 2B

19 CFR 24.5

2. IMPORTER NUMBER (Fill in one format.)

(b) (4)

2A. IRS Number

(b) (4)

2B. Social Security Number

2C. ☐ Check here if requesting a
Customs Assigned Number and
Indicate reason (e). (Check all that apply)☐ I have no IRS No.☐ I have no
Social Security No.☐ I have not applied
for either number.☐ I am not a
U.S. resident

2D. Customs-Assigned Number

RETURN TO :.

AWB REF #:

3. Importer Name

(b) (4)

(b) (4)

4. DIV AKA DBA

☐ DIV ☐ AKA ☐ DBA

5. DIV AKA DBA Name

6. Type

☒ Corporation☐ Partnership☐ Sole Proprietorship☐ Individual☐ U.S. Government☐ Other

7. Importer Mailing Address (2 32-character lines maximum)

(b) (4)

(b) (4)

(b) (4)

11. Country ISO Code (Non-U.S. Only)

(b) (4)

12. Importer Physical Location Address (2 32-character lines maximum; see instructions)

(b) (4)

ACCOUNT

(b) (4)

14. State Code
(b) (4)

15. ZIP

(b) (4)

16. Country ISO Code (Non-U.S. Only)

(b) (4)

17a. Has importer ever been assigned a Customs Importer Number using the same name as in Block 3? ☒ No ☐ Yes (Last number(s) and/or name(s) in Block 17 c.)17b. Has importer ever been assigned a Customs Importer Number using a name different from that in Block 3? ☒ No ☐ Yes (Last number(s) and/or name(s) in Block 17 c.)

17c. If "Yes" to 17a and/or 17b, last number(s) and/or name(s)

NOTE: If the owner or ultimate consignee is a corporation this form must be signed by the president, vice president, secretary, or treasurer of the corporation, or by any employee or any agent of the corporation who holds a power of attorney and a certificate by the corporation that such employee or agent has or will have knowledge of the pertinent facts.

I CERTIFY: That the information presented herein is correct, that if my Social Security Number is used it is because I have no IRS Employer Number, that if my Customs-assigned number is used it is because I have neither a Social Security Number nor an IRS Employer Number, that if none of these numbers is used, it is because I have none, and my signature constitutes a request for assignment of a number by Customs.

18. Printed or Typed Name and Title

(b) (7)(C)

20.

X

19. Telephone No. including Area Code

PHONE

FAX


(b) (4)

21. Date

11-22-2010

22. Broker Use Only

CUSTOMS FORM 5106 (012293)

**Arkansas Department of Correction**

Wendy Kelley
Deputy Director of Health &
Correctional Programs
P.O. Box 8707
Pine Bluff, Arkansas 71611-8707
Phone: (870) 267-6361
Fax: (870) 267-6363
WENDY.KELLEY@ARKANSAS.GOV

FAX COVER SHEET

SEND TO: *Jaquelyn Biddford* FROM: *Wendy Kelley*
FAX #: *901.333.3579* DATE: *9.27.10*
TOTAL PGS (INCLUDING COVER): *3*

Comments:

PLEASE NOTE: This facsimile and any attachments is the property of the State of Arkansas and may be protected by state and federal laws governing disclosure of private information. It is for the intended recipient only. If an addressing or transmission error has misdirected this facsimile, please notify the sender. If you are not the intended recipient you may not use, disclose, distribute, copy, print or rely on this facsimile. You are notified that the document(s) provided may contain health information that is legally privileged, confidential and protected by law from disclosure. Copying or distributing this information except as required for the direct care and treatment of the designated patient, without the express authorization of the Arkansas Department of Correction, Office of the Administrator of Mental Health or Medical Services, is prohibited.

**Arkansas Department of Correction**

Wendy Kelley
Deputy Director of Health &
Correctional Programs
P.O. Box 8707
Pine Bluff, Arkansas 71611-8707
Phone: (870) 267-6361
Fax: (870) 267-6363
WENDY.L.KELLEY@ARKANSAS.GOV

September 10, 2010

Dream Pharma Ltd.
ATTN: Matt Alavi
176 Horn Lane
Action, London W3 6PJ

SUBJECT: Thiopental Injection Purchase

Dear Mr. Alavi,

The Arkansas Department of Corrections (GDC) uses Thiopental Injection to carry out Capital Punishment in Arkansas. In accordance Arkansas State Law, A.C.A. § 5-4-617, "The sentence of death is to be carried out by intravenous lethal injection of one (1) or more chemicals, as determined in kind and amount in the discretion of the Director of the Department of Correction. The chemical or chemicals injected may include one (1) or more of the following substances: one (1) or more ultra-short-acting barbiturate, one (1) or more chemical paralytic agents, potassium chloride, or any other chemical or chemicals, including but not limited to saline solution." The Director of the Arkansas Department of Correction by Administrative Directive has ordered that sodium pentothal or Thiopental sodium be used for the first chemical.

The Arkansas Department of Correction placed an order earlier this year with a manufacturer in the United States, but has been advised that they have none in stock, nor is any expected this year. In order to carry out the State of Arkansas' constitutional mandates in death penalty cases, we desire to make the following purchase:

Name/Description Quantity	Quantity	Price (ea)	Total
Thiopental Injection, power for reconstitution, thiopental sodium, 500mg vial packs of 25's	(b) (4)	(b) (4) GBP	590.25 GBP

Shipping Location:

**Arkansas Department of Correction
Central Administration Office
ATTN: Wendy Kelley, Deputy Director
6814 Princeton Pike
Pine Bluff, AR 71602-9411
Telephone: 870-550-7307**

United States Drug Enforcement Agency Number (DEA): FA1835199

Our Federal Express account is (b) (4)

I understand the expiration date of the chemical currently available is February 2014. I can be reached by telephone at 001-870-550-7307 or by e-mail: wendy.kelley@arkansas.gov

Sincerely,



**Wendy L. Kelley,
Deputy Director for Health & Correctional Programs
Arkansas Department of Corrections**

Trepagnier, Timothy

From: Thomas, David
Sent: Monday, September 27, 2010 2:08 PM
To: Schafer, Patricia; Halpenny, Susan M; Dixon, Ruth P; Boling, Randy N
Cc: Strickland, Evanguel; Solis, Daniel; 'cflanag@azcorrections.gov'; 'michael.dean@dhs.gov'
Subject: RE: Lethal Injection Pharmacology

Patricia:

Correspondence received, thank you. I will email your staffing the Entry number once transmitted.

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office

From: Schafer, Patricia
Sent: Monday, September 27, 2010 10:02 AM
To: Thomas, David; Halpenny, Susan M; Dixon, Ruth P; Boling, Randy N
Cc: Strickland, Evanguel; Solis, Daniel; 'cflanag@azcorrections.gov'; 'michael.dean@dhs.gov'
Subject: Re: Lethal Injection Pharmacology

Susan, Ruth and Randy-- please read this email.

David Thomas- thank you for your email. I will be out of the office for about 2.5 weeks. Please keep my staff aware of this shipment and others.

Thanks, Patt Schafer
Patricia Schafer,

Director, Compliance Branch and Import Operations
New Orleans District Office

From: Thomas, David
To: Schafer, Patricia
Cc: Strickland, Evanguel; Solis, Daniel; 'CHARLES FLANAGAN' <cflanag@azcorrections.gov>; 'DEAN, MICHAEL K' <michael.dean@dhs.gov>
Sent: Mon Sep 27 12:03:04 2010
Subject: Lethal Injection Pharmacology

Ms. Schafer:
FDA Supervisor SCSO:
Memphis, TN

RE: Lethal Injection Pharmacology arrival

These drugs will be coming in on a (b) (4) flight from U.K. tomorrow, with destination Port of Entry Phoenix, 2605. At this writing, the Entry has not been made by filer 575, Arizona Customs Brokerage, 602-273-0912. I will advise you of the Entry number once it has been transmitted ABI.

Please do not detain this entry. The product is scheduled for immediate delivery to Arizona Corrections Department upon arrival and examination at Phoenix, Port of Entry, 2605.

Should you have any questions, please notify me immediately at the contact information below.

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office
480-829-7396 x 12

-----Original Message-----

From: Thomas, David
Sent: Monday, September 27, 2010 8:23 AM
To: Taube, Anthony C
Cc: Strickland, Evanguel; Solis, Daniel; 'DEAN, MICHAEL K'; 'CHARLES FLANAGAN'
Subject: Lethal Injection Pharmacology
Importance: High

Prior Notice Center Director, Anthony Taube:

RE: Lethal Injection pharmacology:

Sir:

I have an entry of 3 components of a lethal injection, 1) Thiopental, 2) Pancuronium, 3) Potassium Chloride departing London this afternoon, destination Memphis with Port of Entry 2605, Phoenix. As of this communication, no entry has been made.

These pharmaceuticals are needed to carry out an execution here in Arizona, and are not for public consumption. Attached is Please find attached explanatory documentation and DEA registration for the Arizona Corrections facility.

Lastly, should I be advising anyone else?

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office

Charles:

We are in receipt of your communication and PDF attachments. I have CC'd my Supervisor, Mr. Strickland, and our

FDA_08.18.11_000145

2/4/2011

Imports Director Mr. Solis for their review.

David Thomas, DCM
FDA Investigations
Phoenix, Office

-----Original Message-----

From: CHARLES FLANAGAN [<mailto:CFLANAG@azcorrections.gov>]
Sent: Friday, September 24, 2010 5:04 PM
To: Thomas, David
Subject: Pharmaceuticals from Dream Pharma, LTD. of London, England

Good Afternoon Mr. Thomas:

Thank you so much for your assistance with this matter. I have attached to this email a copy of the correspondence what will be shipped with the pharmaceuticals. It also includes the Department of Corrections' "Substance Control Registration Certificate". The second attachment is a list of the items that will be shipped to our facility; to include quantities purchased and the last attachment is the revised DEA Registration which includes certification for Schedule 2 drugs.

Once again, thank you again for your assistance. Should you require additional information, please do not hesitate to contact me. Here is my information:

Charles Flanagan
Deputy Director
Arizona Department of Corrections
1601 W. Jefferson - MC 445
Phoenix, Arizona 85007
(602) 542-3611 Office
(602) 377-5334 Cell
(602) 364-0601 Fax
cflanag@azcorrections.gov

<<Thomas, David - FDA Investigations (London Shipment) 2010-09-24.pdf>> <<DOC092310_1.pdf>> <<DEA Registration.pdf>>

Trepagnier, Timothy

From: Schafer, Patricia
Sent: Monday, September 27, 2010 12:02 PM
To: Thomas, David; Halpenny, Susan M; Dixon, Ruth P; Boling, Randy N
Cc: Strickland, Evanguel; Solis, Daniel; 'cflanag@azcorrections.gov'; 'michael.dean@dhs.gov'
Subject: Re: Lethal Injection Pharmacology

Susan, Ruth and Randy-- please read this email.

David Thomas- thank you for your email. I will be out of the office for about 2.5 weeks. Please keep my staff aware of this shipment and others.

Thanks, Patt Schafer
Patricia Schafer,

Director, Compliance Branch and Import Operations
New Orleans District Office

From: Thomas, David
To: Schafer, Patricia
Cc: Strickland, Evanguel; Solis, Daniel; 'CHARLES FLANAGAN' <cflanag@azcorrections.gov>; 'DEAN, MICHAEL K' <michael.dean@dhs.gov>
Sent: Mon Sep 27 12:03:04 2010
Subject: Lethal Injection Pharmacology

Ms. Schafer:
FDA Supervisor SCSO:
Memphis, TN

RE: Lethal Injection Pharmacology arrival

These drugs will be coming in on a (b) (4) flight from U.K. tomorrow, with destination Port of Entry Phoenix, 2605. At this writing, the Entry has not been made by filer 575, Arizona Customs Brokerage, 602-273-0912. I will advise you of the Entry number once it has been transmitted ABI.

Please do not detain this entry. The product is scheduled for immediate delivery to Arizona Corrections Department upon arrival and examination at Phoenix, Port of Entry, 2605.

Should you have any questions, please notify me immediately at the contact information below.

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office
480-829-7396 x 12

-----Original Message-----

From: Thomas, David

Sent: Monday, September 27, 2010 8:23 AM

To: Taube, Anthony C

Cc: Strickland, Evanguel; Solis, Daniel; 'DEAN, MICHAEL K'; 'CHARLES FLANAGAN'

Subject: Lethal Injection Pharmacology

Importance: High

Prior Notice Center Director, Anthony Taube:

RE: Lethal Injection pharmacology:

Sir:

I have an entry of 3 components of a lethal injection, 1) Thiopental, 2) Pancuronium, 3) Potassium Chloride departing London this afternoon, destination Memphis with Port of Entry 2605, Phoenix. As of this communication, no entry has been made.

These pharmaceuticals are needed to carry out an execution here in Arizona, and are not for public consumption. Attached is Please find attached explanatory documentation and DEA registration for the Arizona Corrections facility.

Lastly, should I be advising anyone else?

Respectfully,

David Thomas, DCM
FDA Investigations
Phoenix, Office

Charles:

We are in receipt of your communication and PDF attachments. I have CC'd my Supervisor, Mr. Strickland, and our Imports Director Mr. Solis for their review.

David Thomas, DCM
FDA Investigations
Phoenix, Office

-----Original Message-----

From: CHARLES FLANAGAN [<mailto:CFLANAG@azcorrections.gov>]

Sent: Friday, September 24, 2010 5:04 PM

To: Thomas, David

Subject: Pharmaceuticals from Dream Pharma, LTD. of London, England

Good Afternoon Mr. Thomas:

Thank you so much for your assistance with this matter. I have attached to this email a copy of the correspondence what will be shipped with the pharmaceuticals. It also includes the Department of Corrections' "Substance Control Registration

FDA_08.18.11_000148

2/4/2011

Certificate". The second attachment is a list of the items that will be shipped to our facility; to include quantities purchased and the last attachment is the revised DEA Registration which includes certification for Schedule 2 drugs.

Once again, thank you again for your assistance. Should you require additional information, please do not hesitate to contact me. Here is my information:

Charles Flanagan
Deputy Director
Arizona Department of Corrections
1601 W. Jefferson - MC 445
Phoenix, Arizona 85007
(602) 542-3611 Office
(602) 377-5334 Cell
(602) 364-0601 Fax
cflanag@azcorrections.gov

<<Thomas, David - FDA Investigations (London Shipment) 2010-09-24.pdf>> <<DOC092310_1.pdf>> <<DEA
Registration.pdf>>